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 I 
Abstract 
 
Osteoarthritis (OA) is a common joint disorder with increasing impact in an 
aging society. To understand its pathogenesis, molecular profiling such as RNA 
expression or DNA methylation for diseased tissues has been reported; however, little 
consensus between expression and DNA methylation has been achieved. On the other 
hand, chromatin variations in OA are so far unexplored, mainly due to the technical 
difficulties in applying traditional epigenomic tools on clinical samples. 
 In this study, I employed an epigenomic method, Assay for Transposase-
Accessible Chromatin with high throughput sequencing (ATAC-seq), to characterize 
the genome-wide chromatin alterations associated with OA. A novel protocol to 
generate high-quality ATAC-seq data from fresh hard tissue, human cartilage was first 
established using collagenase II to study human OA disease. Approximately 50,000 
chondrocytes nuclei of fresh knee joint tissues were suitable for ATAC-seq library 
preparation. The quality check qPCR method can be used before sequencing to test the 
signal to the noise ratio.  
In total 109,215 accessible chromatin regions for cartilages were identified, of 
which 71.1% were annotated as enhancers and 16.9% were annotated as promoters. 
Integrating the epigenomic data of clinically relevant tissues with the publicly available 
genetic and transcriptomic data allowed to better understand how the identified loci 
may contribute to OA pathogenesis. Most of these annotated accessible enhancers were 
linked to their putative target genes using public datasets. With this enhancer-gene map 
in chondrocyte, it can better interpret the previously identified OA GWAS (Single 
Nucleotide Polymorphisms) SNPs or OA differential methylated loci located lie outside 
of the coding regions. To identify the chromatin signatures relevant to OA, differential 
accessibility analysis was performed between outer region of lateral tibial plateau (oLT) 
and inner region of medial tibial plateau (iMT), significantly differentially accessible 
peaks were determined with false discovery rate (FDR) ≤ 0.05. Out of the 4,450 
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differentially accessible peaks, 1,565 are more accessible and 2,885 are less accessible 
in the damaged tissues compared to the intact tissues. 
Further analyses for differential accessible enhancer regions showed bone-
related enhancers are more likely to be dysregulated in OA diseased tissue. Consistently, 
371 protein-coding genes that are dysregulated both at the transcriptomic (RNA-seq) 
and epigenomic (ATAC-seq) levels in OA with concordant direction of change. These 
genes are enriched for pathways regulating chondrogenesis, ossification, and 
mesenchymal stem cell differentiation.  
Moreover, integrating ATAC-seq data with publicly available database also 
allowed to identify altered cis-regulatory elements as well as transcription factors 
binding. Taken together, abnormal self-healing in OA knee cartilage was observed in 
this study, suggesting induced endochondral ossification-like cartilage-to-bone 
conversion is a characteristic of OA progression.  
In conclusion, this study demonstrated genome-wide investigations of 
accessible chromatin regions is powerful in probing changes of regulatory genomic 
elements in clinical samples relevant to a disease. These detected regulatory elements 
can potentially serve as biomarkers or therapeutic targets for OA.   
 
Keywords:  Osteoarthritis, epigenetic, cartilage, enhancer, chromatin accessibility, 
ATAC-seq, RNA-seq, DNA methylation, GWAS 
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Chapter 1 General introduction 
 
1.1 Osteoarthritis  
The literal meaning of Osteoarthritis (OA) is bone arthritis, that infers one type 
of arthritis and joint inflamed.  
Arthritis is a common joint disease. Joints (articulations or articulate surfaces) 
are the locations where two or more bones meet in a sense, and there are mainly three 
types of joint judging on moveable, semi-moveable and unmovable, which are 
respectively to synovial joint, cartilaginous joint and fibrous joint. Commonly what 
people know and perceive are the synovial joints. Synovial joint is filled with synovial 
fluid and the most movable type of joint in mammal. Arthritis occurs most often in 
synovial joint such as the knee, hip, lower back and neck (Jacobson et al., 2008). 
Arthritis is not a single disease. It could be more than 100 types (i.e. 
degenerative arthritis, rheumatoid arthritis, inflammatory arthritis, infectious arthritis, 
and metabolic arthritis). The common arthritis symptoms are joint pain, swelling, 
stiffness and decreased ranges of motion. Majority of the estimated arthritis is 
degenerative arthritis, known as osteoarthritis (Neogi, 2013) and rheumatoid arthritis 
(Scott et al., 2010).  
Osteoarthritis (OA), a degenerative joint chronic disease, is resulting in the 
degeneration of joint overlying articular cartilage and underlying subchondral bone 
(Chou et al., 2013; Radin & Rose, 1986), also known as bone-to-bone arthritis or a 
physiologic imbalance induced “joint failure” (Radin & Rose, 1986). The bone under 
the cartilage called subchondral bone is smooth and provides support to the articular 
cartilage (Radin & Rose, 1986), however in the severe OA diseased joint the overlying 
cartilage has been worn out over time, leading to the underlying subchondral exposure 
and bone ends rubbing together. Apparently, the OA patients will be suffering it with 
the excruciating pain and local inflammation; moreover, it could further aggravate the 
joint degeneration and permanently damage the bone. Therefore, OA is representing 
one of the most common causes of chronic disability in the world. 
In contrast to OA, rheumatoid arthritis (RA) is inflammatory arthritis and 
autoimmune disorder disease that the joints are eroded by uncontrolled inflammation, 
and affects the entire body (Beasley, 2012). There is less-inflammation or non-
inflammation in most of the cases in OA.  The case of inflammation occurred in OA is 
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owing to degeneration, which is a subsequent consequence of OA. In the early stage of 
OA, it is a condition of cartilage erosion and the bone is largely spared. It is also 
showing minor bone spur growth.  In the late stage of OA, the breakdown products of 
cartilage induce a chronic inflammatory response in the synovium and tendon, induced 
the architecture changed by the further mechanical and inflammatory stress (Grynpas 
et al., 1991). 
 
1.2 Knee OA 
1.2.1 Current knee OA Statistics 
OA is highly prevalent worldwide. It has been reported that about 30 present of 
US population aged over 60 years has joint problems that could be attributed to primary 
OA – defined as aging-related, as opposed to injury-related secondary OA. A 
population-based Framingham Knee Osteoarthritis study suggested that knee OA 
increases in prevalence throughout the elderly people, and it occurs more common in 
women than men (Felson, 1990), with most prevalent in the knee (Anderson & Loeser, 
2010). Currently, Knee OA is the most challengeable joint disease due to no effective 
cure to regenerate the original structure and function of the damaged tissue except for 
knee joint replacement surgery. The knee OA has become a common disease with 
increasing impact in an aging society. 
 
1.2.2 Risk factors of knee OA 
Aging is a risk factor of knee OA. Although OA is not just a disease related to 
old people and is not an inevitable consequence of growing old (Loeser, 2009; Muller, 
2009). However, aging has been considered as a primary risk factor for OA progression, 
due to changes in the musculoskeletal system, bone structure rarefaction and bone 
micro damage accumulation (Loeser, 2009; Anderson & Loeser, 2010). Cell replicative 
senescence is a state of irreversible growth arrest in aging (Campisi, 1997), with 
phenomena of shortened telomeres (Jiang et al., 2007), DNA damage (Gensler & 
Bernstein, 1981), chromatin structure changes (i.e. the formation of senescence-
associated heterochromatin) (Loeser, 2009; Muller, 2009). These phenomena are 
mediating aging due to oxidative stress, reactive oxygen species (ROS) or free radicals 
(Harman, 1956). However, the cell senescence process has also been considered as a 
mechanism to prevent cells with damaged DNA from being replicated and thus to 
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protect against tumor formation and cancer development (Collado et al., 2007; Itahana 
et al., 2004). It has been reported that aging-related changes in the cartilage matrix, 
such as increased matrix calcification, fatigue failure, advanced glycation end products 
(AGEs) formation, collagen cleavage, decreased hydration levels and aggrecan size 
could refer to the development of OA (Chubinskaya et al., 2002; DeGroot et al., 2004; 
Mouritzen et al., 2003; Nedić et al., 2013; Rosen et al., 1997; Verzijl et al., 2000; Wells 
et al., 2003; Wilkins et al., 1983). Chondrocytes from older adult exhibit range of 
changes typically cell senescence, such as decreased growth factor levels, telomere 
shortening, increased levels of cytokine and MMP production, up-regulated of 
p21/p53/p16 and SA-ßgal accumulation (Dai et al., 2006; Forsyth et al., 2005; Guerne 
et al., 1995; Hollander et al., 1995; Long et al., 2008; J. A. Martin & Buckwalter, 2001; 
Martin et al., 2004; Yudoh et al., 2005; Zhou et al., 2004). Taken together, aging is 
more likely to be inter-related with OA with but not inter-dependent with OA. 
Gender is a risk factor of knee OA. The knee OA is more common in elder 
female, however, there has not yet clear-cut relationship of osteoarthritis with estrogen 
in female been found (Felson, 1990). The anatomical and kinematic difference between 
male and female could be potentially involved as the main factor. 
Obesity is a risk factor of knee OA. The association of obesity and knee OA has 
been well known as a risk factor beyond the pathogenic mechanisms, such as the weight 
induced a direct systemic effect on joints and obesity-associated low-grade 
inflammation and oxidative stress (Lee & Kean, 2012). 
 
1.2.3 Diagnosis of knee OA 
The destruction of the cartilage, joint space narrowing and bony spur formation 
(bony abnormality) are the main features of OA (Krane et al., 2001).  Imaging methods 
such as X-ray and Magnetic resonance imaging (MRI) scan are commonly used for 
knee OA diagnosis. And clinical examination included age (> 50 years old), morning 
stiffness (< 30 minutes), crepitus on active motions, bony enlargement can also be used 
as a diagnosis of knee osteoarthritis (Altman et al., 1986). 
 
1.2.4 Treatments for knee OA 
The pathogenesis of OA is still unclear and lack of treatment to cure the early 
process of chondral degeneration (Ringdahl & Pandit, 2011). Commonly applied 
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treatment for knee OA are healthy weight maintains, medication of pain and anti-
inflammatory, steroid injections and surgery for repairing the severely damaged joint. 
Currently, the trials on stem cell research will be a potential treatment for OA aiming 
to regenerated the degraded cartilage using patient own cells other than alleviating the 
pain (Pas et al., 2017). 
 
1.3 Cartilage and subchondral bone 
Cartilage is a resilient, flexible, smooth and connective elastic tissue, which is 
composed of unique and specialized cells called chondrocytes, large amounts of type II 
collagenous extracellular matrix, proteoglycan and elastin fibers (Figure 1-1). The 
extracellular matrix, proteoglycan and elastin fibers are all produced from chondrocytes. 
It has been identified that there are mainly three types of cartilage in human, hyaline 
cartilage, fibrocartilage, and elastic cartilage, based on the relative amounts of type II 
collagen and proteoglycan.  
Particularly, cartilage is an avascular and aneural tissue, which does not contain 
blood vessels or nerves. A physics process diffusion is applied to assist chondrocytes 
nutrition from the surrounding fluid flow and underlying subchondral bone (Pan et al., 
2009). Compared with other tissue, cartilage has very low self-repair ability. 
Subchondral bone refers to the bony components lying distal to calcified 
cartilage, which is separated into two distinct anatomic entities: subchondral bone plate 
and subchondral trabecular bone (Goldring & Goldring, 2010; Grynpas et al., 1991; 
Imhof et al., 1999; Li et al., 2013; Madry et al., 2010; Milz & Putz, 1994). Subchondral 
bone sclerosis, together with progressive cartilage degradation, has been widely 
considered as hallmark symptoms of OA (Figure 1-2). Additionally, articular cartilage 
overlies subchondral bone, by the depth, it encompasses superficial non-calcified 
cartilage and deeper calcified cartilage. Calcified cartilage is permeable to small 
molecule transport, and biochemically interacting between non-calcified cartilage and 
subchondral bone ( Li et al., 2013). 
 
1.4 Epigenetic studies 
In an organism, all somatic cells share the same DNA sequence copied from the 
fertilized egg. However, the cell fate and function change in terms of the different gene 
or group of genes are working at the different time and different cell types. Epigenetics 
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is a phenomenon that facilitates temporal and spatial regulation of gene expression 
independent of changes to the underlying DNA sequence and includes DNA 
methylation, histone modifications, non-coding RNAs (including micro-RNAs) and 
chromatin accessibility. In contact to the irreversible genetic variations induced 
diseases, the reversible epigenetic dysregulation has been attached more and more 
importance on disease pathogenesis (Haluskova, 2010; Portela & Esteller, 2010). The 
epigenetic phenomenon is heritable phenotype changing by gene switch on or off, and 
it is common for normal development such as X-chromosome inactivation (Disteche & 
Berletch, 2015) and stem cell differentiation (H. Wu & Sun, 2006). The epigenetic 
regulation can potentially induce aging and diseases. 
 
1.4.1 Chromatin structure  
It is widely accepted that the regulation of chromatin structure is a pivotal 
epigenetic phenomenon (Margueron & Reinberg, 2010). In eukaryotic cells, chromatin 
can be found, which is the combination of histone protein and genetic complement 
(DNA and RNA). DNAs is warping with histone proteins and linking RNAs or other 
regulatory elements can be regulating the structure of each chromatin to form the 
dynamic chromatin structure. In each organism, all somatic cells also contain the same 
number of chromatins except for chromatin structure. A nucleosome is the basic unit 
of chromatin, consisting of 146 DNA nucleotide pairs and 8 histone protein cores. Gene 
activation is in terms of gene transcription, which demands the regulatory elements 
access and bind the right loci in the genome to switch on or off the gene transcription. 
In other words, DNA in open chromatin regions are not tightly packed, and the 
regulators such as some transcription factors and polymerases can only access the open 
chromatin regions (Figure 1-3), such as active enhancers and promoters. Open 
chromatin that is also known as euchromatin, in contract to heterochromatin, is 
correlated with active regulatory elements and the dysregulation will be critical in 
diseases. 
 
1.4.2 ATAC-seq 
Chromatin accessibility has been conventionally carried out by using MNase-
seq or DNase-seq required millions of cells (Tsompana & Buck, 2014). However, in 
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the past few years, it has been greatly improved by using prokaryotic Tn5 transposase  
(Adey et al., 2010).  
Assay for Transposase Accessibility Chromatin with high-throughput 
sequencing (ATAC-seq) is a method for mapping chromatin accessibility genome-wide 
(Buenrostro et al., 2015). Transposase can catalyze the transposons movement in the 
genome. The mutated hyperactive Tn5 transposase used in ATAC-seq has high-level 
activity than the naturally occurring ones allows Tn5 transposons can easily cut the 
exposed DNA and ligate the specific next-generation sequencing adaptor sequences at 
each end. In the intact nuclei, only the open chromatin regions can be accessed and cut 
by Tn5 transposon. The adapted DNA library sequences after PCR amplification can 
be sequenced by Illumine sequencer (Figure 1-4). In addition, ATAC-seq enables 
detection of accessible chromatin with fewer cells than other methods with the use of 
MNase-seq or DNase-seq. By using the bioinformatics, the sequenced DNA can be 
aligned and mapped to the genome. ATAC-seq method and analysis can profile the 
closed and open chromatin regions genome-wide in different cells. 
 
1.5 Research objectives 
OA is a degenerative joint disease (Findlay & Kuliwaba, 2016; Goldring & 
Goldring, 2010) that is one of the most common causes of chronic disability in the 
world (Kwoh, 2012; Martel et al., 2016), of which the knee OA is the most common. 
Main features of OA include cartilage degradation, subchondral bone thickening, joint 
space narrowing and osteophytes formation (Krane et al., 2001), resulting in stiffness, 
swelling, and pain in the joint. Currently available treatments are either pain relief or 
joint function improvement by strengthening the supporting muscles. However, OA 
progression ultimately leads to costly total joint replacement surgery, making it a 
growing global health burden. 
Although the causes of OA are not well understood, risk factors such as age, 
weight, gender, and genetic factors have been identified (Martel et al., 2016). Several 
models for OA initiation, such as mechanical injury, inflammatory mediators from 
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synovium, defects in metabolism and endochondral ossification, have been proposed to 
explain pathogenesis of this disease (Cox et al., 2013; Dreier, 2010; Kapoor, 2015; 
Kawaguchi, 2008, 2016; Kuyinu et al., 2016; Man & Mologhianu, 2014). To date, 
GWAS have identified more than 20 loci to be associated with the risk of developing 
OA (Uhalte et al., 2017). While next-generation sequencing data is being generated to 
discover rare variants with larger effect size, the identified variants are often located in 
the non-coding regions of the genome (Corradin & Scacheri, 2014), complicating the 
identification of the causal genes. Transcriptomic analyses of cartilage in diseased 
joints of OA patients (taken from the replacement surgeries) provided an opportunity 
to pinpoint transcriptionally dysregulated genes and pathways relevant to OA (Chou et 
al., 2013; Dunn et al., 2016). However, such studies have yet to fully reveal the 
underlying molecular mechanism of how the transcriptions of these genes are 
dysregulated. 
Recently, epigenetic tools have been applied to gain further insight into the 
pathogenesis of OA. There have been reports of DNA methylation status (den 
Hollander et al., 2014; Fernández-Tajes et al., 2014; Reynard, 2017; Rushton et al., 
2014) in the cartilage of diseased joints. Some of the reports have also revealed the 
epigenetic marks are potential as mediators of OA genetic risk (den Hollander & 
Meulenbelt, 2015; den Hollander et al., 2015; Reynard, 2017; Meurs, 2017).  However, 
the change of gene expression is rarely associated with DNA methylation alterations at 
promoters (Chou et al., 2013, 2015; Zhang et al., 2016). Many of the identified 
differentially methylated sites, in fact, fall in enhancer regions (den Hollander et al., 
2015; Rushton et al., 2014; van Meurs, 2017), which are non-coding regulatory 
elements, disruption of which may lead to dysregulated transcription, and many are cell 
type-specific (Bernstein et al., 2012; Herz, 2016). Recent large-scale studies, such as 
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FANTOM5 (Forrest et al., 2014), Roadmap Epigenomics Project (Bernstein et al., 2010) 
and GTEx (Lonsdale et al., 2013) have enabled the prediction of regulatory networks 
between enhancers and their potential target genes (e.g. JEME (Cao et al., 2017)), 
which could be applied in a clinical context to explore the roles of enhancers in disease 
pathogenesis.  
Here, this study was designed to investigate alterations of enhancers associated 
with OA by applying ATAC-seq (Buenrostro et al., 2015) on the knee joint cartilages 
from OA patients, using an optimized protocol for cartilage sample preparation. ATAC-
seq maps the accessible chromatin regions, which are often regulatory regions such as 
promoters and enhancers that play roles in regulation of gene expression. By integrating 
our ATAC-seq data with the publicly available genetic, transcriptomic and epigenomic 
data, dysregulated enhancers and their potential target genes were identified. This data 
highlights a number of OA risk loci and differentially methylated loci (DML) that 
potentially play roles in cartilage degradation during OA development. 
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Figure 1-1 Diagram of cartilage matrix major components 
Articular cartilage is comprised of chondrocytes surrounding by a matrix of collagens 
(blue line), proteoglycans (red “bottle brush”) and hyaluronan (yellow line). 
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Figure 1-2 Articular cartilage and subchondral bone in normal and diseased 
conditions. 
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Figure 1-3 Interphase of Chromatin. 
Euchromatin region is accessible, considered as active region; heterochromatin region 
is inaccessible, considered as silent region.  
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Figure 1-4 Tn5 tagmentation at open chromatin region. 
ATAC-seq used the Tn5 transposome can access to the open chromatin and ligate the 
illumine adaptor sequence, and only the adapted DNA sequence can be further 
amplified and sequenced (Buenrostro et al., 2015).  
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Chapter 2 ATAC-seq library preparation using flash frozen 
and fresh hard tissue 
 
2.1 Introduction 
OA has a strong heritable component that is polygenic in nature. However, 
difficulty in identifying susceptible genes for the disease suggests epigenetic 
components may be an important factor in the progression of the disease. To date there 
have been DNA methylation studies on OA (den Hollander & Meulenbelt, 2015), 
however they are not able to effectively establish the causes for differential expressions 
in disease samples. Previously developed a unique and proven method was used for 
extracting high quality material of both normal (or early) and late disease tissues from 
the same individual donor knee, where accurately isolated chondrocytes from, 
providing an excellent control for individual-level cofounders (Chou et al., 2013).  
         To investigate chromatin signatures in articular cartilage associated with OA, 
ATAC-seq were performed on the chondrocytes isolated from the knee joints of 
patients. In this study, the ATAC-seq library quality assessed comparing with flash-
frozen (n=4) and fresh cartilage (n=8) tissues, according the perversely published tibial 
plateau section method (Chou et al., 2013), as a model for OA disease progression, 
including outer region of lateral tibial plateau (oLT) exhibited macroscopically normal 
cartilage with a visibly smooth cartilage surface, inner region of lateral tibail plateau 
(iLT) showed intermediate erosion and sufficient cartilage to detect visible fissures on 
tissue cross-section, and inner region of medial tibial plateau (iMT) had visible most 
severe erosion of cartilage (Figure 2-1). 
 
2.2 Materials and methods 
2.2.1 Knee joint tissues 
Human knee joint tibial plates were collected from patients who undertook joint 
replacement surgery due to severe primary OA at the National Hospital Organization 
Sagamihara Hospital (Kanagawa, Japan). Demographic information for patients is 
listed in Table 2-1. The diagnosis of OA was based on the criteria of the American 
College of Rheumatology (Altman et al., 1986), and all the knees were medially 
involved in the disease. All the tibial plateaus had medial and lateral compartment 
 14 
dominant of cartilage erosion. Flash frozen knee joint tissue collected were immediately 
stored in liquid nitrogen and subsequently stored in –80°C; fresh knee joint tissue was 
incubated in 4°C centigrade cultured medium after surgery in less than 6 hours. 
Informed consent was obtained from each patient enrolled in this study. This study was 
approved by all the participating institutions (Sagamihara National Hospital, University 
of Tokyo and RIKEN) with the approval NO. Yokohama H17-23(6). 
 
2.2.2 Cartilage processing 
It has previously shown that the oLT region (outer region of the lateral tibial 
plateau, representing the intact cartilage) is a good control for comparing the iMT 
region (inner region of medial tibial plateau, representing the damaged cartilage) as a 
model for OA disease progression (Figure 2-2) (Chou et al., 2013). The previous studies 
have assessed that these regions could encompass range of histological normal and 
severity in knee cartilage   (Chou et al., 2013; Chou et al., 2015).   
The chondrocytes were washed with cold PBS (centrifuge at 500 g for 5 minutes 
at 4°C). Fresh cartilage was sectioned by using a scalpel (Figure 2-3), and flash frozen 
knee cartilage was sectioned in liquid nitrogen by using a previous set up custom work 
platform and followed by thawing with bathing in Dulbecco's Modified Eagle Medium 
and digestion (Figure 2-4). 100 mg cartilage from each region was sectioned and 
digested with 0.2% Collagenase Type II (Sigma-Aldrich) at 37°C with rotation for 12 
hours to remove matrix debris. No culturing or sorting for purifying chondrocytes, 
immediately counted approximate 50,000 chondrocytes manually by a cell counting 
chamber Incyto C-Chip (VWR) and collected by centrifugation at 500 g for 5 minutes 
at 4°C.  
 
2.2.3 Nuclei extraction 
Approximately 50,000 chondrocytes nuclei from both oLT and iMT region of 
each patient were extracted via homogenizing in 50 L of pre-cooling and freshly 
prepared lysis buffer (10 mM Thris.HCl, pH 8.0, 10 mM NaCl, 3 mM MgCl2 and 0.1% 
(v/v) Igepal CA-630) on ice and immediately centrifuged at 500 g for 10min at 4°C 
according to the original protocol (Buenrostro et al., 2015). 
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2.2.4 Tagmentation 
Tn5 transposase (TDE1) and 2 reaction buffer (TD) were from purchased 
Nextera kit (Iluumina). Each tagmentation reaction master mix contains 25 L TD, 2.5 
L TDE1 and 22.5 L nuclease free water. 50,000 chondrocyte nuclei were suspended 
in cold reaction master mix by gently pipetting, avoided making any air bubbles at this 
step. Reaction was incubated at 37°C for 30 minutes.  
 
2.2.5 DNA purification 
The Transposed DNA were purified by using MinElute PCR purification kit 
(allowed to purify up to 5 ug PCR products between 70 bp to 4 kb in low elution volume; 
Qiagen). The DNA was eluted in a final 12 l elution buffer. 1ul loaded into a 
NanoDrop spectrophotometer (ND-1000) to validate the consistency.  
 
2.2.6 PCR amplification 
10 L transposed DNA was amplified by mixing with 2.5 l custom PCR 
forward primer (Ad1.0), 2.5 L custom PCR reversed barcoded primers (Ad2.n), and 
25 L NEBNext High-Fidelity 2 PCR Master mix (Bao et al., 2015).  Thermal cycler 
condition is 1 (72°C, 5 minutes; 98°C, 30 seconds), (5 + addition cycles) (98°C, 10 
seconds; 63°C, 30 seconds; 72°C, 1 minute). Addition cycles were determined as 
previously published method by using qPCR (Buenrostro et al., 2015). 
 
2.2.7 Size selection and distribution 
After ATAC-seq libraries purified, I used Agencourt AMPure XP (1:1.5 and 1: 
0.5 sample to beads; Beckman Coulter) for twice size selection, only kept the 100 bp 
to 1,000 bp length DNA for illumine sequencing. This step would filter out the PCR 
primers and large DNA fragments which cannot be sequenced in sequencer. The size 
distribution can be assessed by using bioanalyzer (Agilent Technologies). 
 
2.2.8 Quality check by qPCR 
Library quality was assessed before sequencing by qPCR enrichment of a house 
keeping gene promoter (GAPDH) over a gene desert region (Milani et al., 2016). Primer 
sequences are shown in Table 2-2 (Milani et al., 2016). Briefly, for each PCR reaction, 
mix 1 µL library DNA (1 ng/µL), 10 µL SYBR Premix ExTaq RnaseH plus 
 16 
(TAKARA), 0.8 µL forward primer (10 µM), 0.8 µL reverse primer (10 µM), 0.4 µl 
ROX reference dye II (TAKARA), 7.8 µL nuclease-free water. Thermal cycler 
condition is 1 (95.0°C, 30 seconds) initial denaturation, 40 (95°C, 5 seconds; 60°C, 
34 seconds) annealing and extension, 1 (95°C, 15 seconds; 60°C, 60 seconds; 95°C, 
15 seconds; 60°C, 15 seconds) final extension. 
 
2.2.9 KAPA library quantification and Illumine sequencing 
Molarity of ATAC-seq libraries were quantified by using KAPA library 
quantification kit (KAPA Biosystems). Final contraction for sequencing was 5 pM for 
each lane. ATAC libraries were sequenced on a HiSeq2500 sequencing system (50 bp, 
PE; Illumina) by internal sequencing service group GeNAS (Genome Network 
Analysis Support Facility) in RIKEN Yokohama Japan. 
 
2.3 Results and discussion 
2.3.1 ATAC-seq of chondrocyte from human knee cartilage 
To investigate the variations of chromatin accessibility in cartilage associate 
with OA, I performed ATAC-seq on human articular cartilage tissues, the tibial plateau 
of the human knee primary OA selected after replacement surgery (Figure 2-3, 2-4). It 
has been previously shown that the oLT region (outer region of the lateral tibial plateau, 
representing the intact cartilage) is a good control for comparing the iMT region (inner 
region of medial tibial plateau, representing the damaged cartilage) as a model for OA 
disease progression (Chou et al., 2013), and the transcriptome and methylome of this 
model have been characterized (Chou et al., 2013; Chou et al., 2015; Zhang et al., 2016; 
Zhang et al., 2016). 
All patients were diagnosed as primary OA, which is induced by aging, none of 
the patients were younger than 65-year-old when they undertook the joint replacement 
surgery. The Demographic information of patients were listed in Table 2-1. As excepted, 
female is more suspected to OA, 11 out of 13 patients are female.  
Two regions of the cartilage from each patient were selected as oLT (healthy) 
and iMT (degraded). About 100 mg sectioned cartilage from oLT or iMT region were 
digested by using collagenase II in 37 °C for 12 hours and counted 50,000 live cells for 
ATAC-seq library. The flash frozen joint tissue was sectioned by using a custom tool 
shown in Figure 2-4, however, no live cells after digestion could be observed. 
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2.3.2 ATAC-seq library quality check  
Quality of the libraries prepared from flash frozen or fresh cartilage were both 
assessed. Typically, ATAC-seq library should be generated from live cells and the 
library length should be distributed between 100 bp to 1000 bp, the nucleosome banding 
pattern shown in the bioanalyzer profile prior sequencing serves as a quality control for 
ATAC-seq library (Figure 2-5). However, despite similar bioanalyzer profiles, only 
chondrocytes isolated from fresh cartilage showed enrichment for accessible loci after 
sequencing, (Figure 2-6A) and insertion size distribution pooled profile after 
sequencing (Figure 2-7). This result suggests the chromatin in flash frozen cartilage 
tissue were randomly fragmented during freezing and thrswing. In addition, the 
expected nucleosome banding patterns were observed in the fragment size distribution 
for both oLT and iMT libraries (Figure 2-7). 
In contrary to previously published ATAC-seq protocol comparing fresh and 
flash-frozen neurons (Milani et al., 2016), here the bioanalyzer profile was not 
sufficient to indicate library quality.   
Quantitative real-time PCR was performed on the ATAC-seq library to assay 
enrichment of a known accessible locus (GAPDH promoter) against an intergenic locus 
(negative control) (Milani et al., 2016). The qPCR enrichment is found to be positively 
correlated to signal-to-noise ratio (enrichment in DNase hypersensitive sites) listed in 
the sequencing statistic result (Figure 2-6B; Table 2-3). 
Overall, the libraries are of high quality, showing two- to four-fold enrichment 
in the Roadmap DHS (DHS enrichment score, Methods), with no substantial difference 
between oLT and iMT libraries.  
 Taken together, it can be concluded a qPCR assay of known accessible loci is 
more suitable for ATAC-seq library quality control, and the fresh cartilage tissue is 
necessary to obtain high quality ATAC-seq data. 
 
2.4 Summary 
Conventional epigenomic profiling at the chromatin level, such as chromatin 
immunoprecipitation sequencing (ChIP-seq) and DNase-seq, is informative in 
providing insights into the molecular mechanism underlying the regulation of gene 
expression. However, applying these methods to clinically relevant tissue is less 
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feasible due to the requirement of large number of cells. Especially with the cartilage 
tissues, the limited tissue sampling size and the extracellular matrix make collection of 
sufficient cells difficult. One major advantage of ATAC-seq is that it can be achieved 
with only thousands of cells, making the direct chromatin profiling of clinical samples 
feasible. 
In this study, ATAC-seq on OA samples was applied to obtain a chromatin 
accessibility map in articular cartilage, and identified regulatory regions associated with 
OA.  The lack of normal knee tissues due to difficulties associated with collecting them 
is a limitation for studying OA. However, the previous studies of the pathology and 
transcriptome showed that the oLT regions are very similar to normal (Chou et al., 2013, 
2015). Thus, the oLT regions could serve as a suitable alternative to normal control, 
which could also reduce the inter-individual variations.  
A protocol to generate high quality ATAC-seq data from fresh hard tissue, 
human cartilage was first established using collagenase II to study human OA disease. 
Approximately 50,000 chondrocytes nuclei of fresh knee joint tissues were suitable for 
ATAC-seq library preparation. Quality check qPCR can be used before sequencing to 
test the signal to the noisy ratio. Thus, it can be concluded that the ATAC-seq libraries 
had good and indistinguishable quality between oLT and iMT regions. 
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Table 2-1 Demographic information of patients. 
 
No. Sample ID Patient ID KL-
grade 
Age Gender BMI Left/ 
right 
1 oLT/iMT_01 160908_cartilage_oLT/iMT 4 75 M 29.2 R 
2 oLT/iMT_02 160927_cartilage_oLT/iMT 4 78 F 23.3 L 
3 oLT/iMT_03 161004_cartilage_oLT/iLT/iMT 3 86 F 25.3 R 
4 oLT/iMT_04 161018_cartilage_oLT/iLT/iMT 4 65 F 28.6 L 
5 oLT/iMT_05 161027_cartilage_oLT/iLT/iMT 4 70 F 23.5 R 
6 oLT/iMT_06 161115_cartilage_oLT/iLT/iMT 4 71 F 22.5 L 
7 oLT/iMT_07 161124_cartilage_oLT/iLT/iMT 4 78 F 19.8 R 
8 oLT/iMT_08 161212_cartilage_oLT/iLT/iMT 4 82 F 29.9 R 
9 Frozen_oLT/
iMT_01 
102714YH_oLT/iMT 3 79 F 24.5 R 
10 Frozen_oLT/
iMT_02 
011916KR_oLT/iMT 4 89 F 24.9 R 
11 Frozen_oLT/
iMT_03 
012816K_oLT/iMT 4 79 M 23.9 R 
12 Frozen_oLT/
iMT_04 
120214KL_oLT/iMT 4 80 F 19.5 L 
 
Patient demographic information. Fresh (1-8) and flash frozen (9-12) cartilages were 
sectioned from oLT and iMT region of each patient. 
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Table 2-2 QC RT-qPCR primer sequences (human).  
Sequence (5' to 3') Name 
CATCTCAGTCGTTCCCAAAGT GAPDH gene promoter Fw 
TTCCCAGGACTGGACTGT GAPDH gene promoter Rv 
AACTGGCTAGTAAGGAGTGAATG Gene desert region #1 Fw 
GGGAATGGAAAGAAGTCCACTAT Gene desert region #1 Rv 
GGAAAGTCCCTCTCTCTAACCT B2M gene promoter Fw 
GCGACGCCTCCACTTATATT B2M gene promoter Rv 
CCCAAACTCTGAGAGGCTTATT Gene desert region #2 Fw 
GAGCCATCATCTAGACACCTTC Gene desert region #2 Rv 
 
GAPDH and B2M gene promoter regions are as positive control, and Gene desert 
region # 1 and # 2 are intergenic regions as negative control. 
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Table 2-3 ATAC-seq sequencing statistics. 
 
Sample 
ID 
# raw read # mapped read # chrM read 
# nonduplicated 
read 
# filtered read 
oLT_01 129330614 97392138 27968647 89188491 52297657 
iMT_01 115602248 92405339 30284689 71819478 44450661 
oLT_02 99795730 80640395 21075304 72179831 48677376 
iMT_02 99160898 81480868 1844538 90857673 66041550 
oLT_03 156914266 121116649 26584322 117399759 74446933 
iMT_03 102074864 85253341 22636994 70011859 49032221 
oLT_04 123287032 96967328 27774014 86769095 55275069 
iMT_04 115122568 92890641 11700019 93796683 65913834 
oLT_05 119818700 98934892 46401817 62125879 38103912 
iMT_05 100047428 79155363 12299719 81019253 55052706 
oLT_06 74390722 61100843 12274153 58131197 41235797 
iMT_06 93868388 79771165 16438802 69947345 50727727 
oLT_07 127531074 108328720 33782622 83916201 59527656 
iMT_07 117432404 90581902 5013315 104949457 71187775 
oLT_08 96464546 79464763 17309928 73043617 51451152 
iMT_08 100428630 69917383 5558689 86711144 50794381 
 
Sample 
ID 
Fraction 
of read 
in DHS 
DHS 
enrichment 
Enrichment 
GAPDH 
% mapped % chrM % dup % filter 
# called 
peaks 
oLT_01 0.349 2.696 36.08 75.3 28.7 31 53.7 515175 
iMT_01 0.391 3.282 18.48 79.9 32.8 37.9 48.1 512610 
oLT_02 0.339 2.591 13.85 80.8 26.1 27.7 60.4 539268 
iMT_02 0.257 1.717 2.72 82.2 2.3 8.4 81.1 526132 
oLT_03 0.303 2.167 19.52 77.2 21.9 25.2 61.5 404851 
iMT_03 0.390 3.282 20.22 83.5 26.6 31.4 57.5 480399 
oLT_04 0.331 2.503 8.76 78.7 28.6 29.6 57 491146 
iMT_04 0.356 2.817 11.91 80.7 12.6 18.5 71 410865 
oLT_05 0.450 4.233 31.89 82.6 46.9 48.2 38.5 493423 
iMT_05 0.338 2.6 10.11 79.1 15.5 19 69.6 467217 
oLT_06 0.354 2.808 14.68 82.1 20.1 21.9 67.5 557619 
iMT_06 0.321 2.375 10.92 85 20.6 25.5 63.6 565577 
oLT_07 0.370 3.019 12.49 84.9 31.2 34.2 55 432241 
iMT_07 0.295 2.088 9.25 77.1 5.5 10.6 78.6 477879 
oLT_08 0.354 2.816 14.22 82.4 21.8 24.3 64.7 484188 
iMT_08 0.303 2.179 5.27 69.6 8 13.7 72.6 578185 
 
# raw read: number of raw ATAC-seq reads from the sequencer. 
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# mapped read: number of reads mapped to the reference genome (hg38). 
# chrM read: number of reads mapped to the mitochondrial genome. 
# nonduplicated read: number of the reads after removing PCR duplicates. 
# filtered read: number of reads after all filtering for MACS2 peak calling. 
Fraction of read in DHS: the proportion of filtered reads overlapping Roadmap 
DHS regions. 
DHS enrichment: fold enrichment of reads falling in DHS over randomly 
shuffled region.  
qPCR_enrichment_GAPDH: 2^∆Ct values generated from RT-qPCR assay of 
GAPDH promoter (chromatin accessible) against intergnic region (chromatin 
inaccessible). 
% mapped: percentage of reads mapped to the reference genome (hg38).  
% chrM: percentage of mapped reads map to the mitochondrial genome. 
% dup represents the percentage of duplicated reads in mapped reads. 
% filter: percentage of filtered reads for peak calling.   
# called peaks: number of peaks called by MACS2 for each individual sample.  
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Figure 2-1 Human osteoarthritis (OA) study model system. 
(A) Tibial plateau of the human knee primary OA selected after replacement surgery. 
The black boxes indicate regions for histological analysis and cDNA microarray  (Chou 
et al., 2013), DNA methylation (Zhang et al., 2016) and ATAC-seq. (B) Histological 
analysis of three regions (Zhang et al., 2016).  
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Figure 2-2 Fresh primary knee OA cartilage section for ATAC-seq. 
Outer region of lateral tibial plateau (oLT) with a visibly smooth cartilage surface, and 
inner region of medial tibial plateau (iMT) with visible loss of articular cartilage were 
collected for isolating chondrocytes. 
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Figure 2-3 Flow chart of the study design (fresh). 
Two regions of cartilage from each patient were select as oLT (healthy) and iMT 
(diseased). About 100 mg sectioned cartilage from each region used for collagenase II 
digestion in 37°C for 12 hours with rotation, and counted 50,000 live cells for ATAC-
seq library preparation. 
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Figure 2-4 Custom tools for frozen joint tissue sectioning and cartilage separation. 
(a) Work platform was constructed from commercial components: (1) rotary tool holder, 
(2) high speed rotary motor, (3) custom fixation adapter, (4) 90 angle adaptor, (5) 25 
mm diameter cutting disc of 0.1 mm thickness saw. (b) Knee joint tissue dipped in 
liquid nitrogen (LN) ready for section. (c) Steps of cartilage collection from the frozen 
tibial plateau. 
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Figure 2-5 Bioanalyzer profile overview of ATAC-seq DNA libraries. 
Comparison of fresh and flash frozen samples for ATAC-seq library size distribution 
(open chromatin DNA length plus sequencing adaptor length), majority of ATAC-seq 
library length should be distributed between 100 bp to 1000 bp, the peaks in between 
represents nucleosome free region, mono-nucleosome, de-nucleosome and try-
nucleosome from left to right. 
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Figure 2-6 ATAC-seq quality check with qPCR. 
(A) DNase enrichment score and QC-qPCR can potentially be reflecting the ATAC-
seq library quality, an essential QC of ATAC-seq library. (B) ATAC-seq library QC-
qPCR dCt and ratio of ATAC-seq reads enriched in DNase hypersensitive region is 
positive linear correlation.   
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Figure 2-7 Combined 8 atients ATAC-seq library fragment size distribution. 
Peaks indicating nucleosome free region, mono-nucleosome, de-nucleosome and tri-
nucleosome. Blue curve is pooled 8replicate oLT and red curve is pooled 8replicate 
iMT. X-axis is open chromatin region DNA length and Y-axis is the log normalized 
read counts.  
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Chapter 3 ATAC-seq data analysis 
 
3.1 Introduction 
Bioinformatics has become important, with the increasing genomic and 
epigenomic sequencing technics developed. The NGS data processing include pre-
processing and data analysis. Similar with other sequencing technics ATAC-seq data 
processing pipeline includes sequencing quality check, adapter trimming, alignment, 
removing PCR duplicates, sorting and peak calling. To data there is no available open 
source interactive or user-friendly software (without programming) for NGS data 
processing, and using ATAC-seq data processing pipeline require bioinformatics skills 
such as non-interactive command-line application in Linux or Unix environment and 
programming. 
Epigenetic properties of human genome studies such as chromatin structure and 
DNA methylation, have demonstrated how much epigenetics affect gene translation 
and expression. ATAC-seq is the assay for tn5 transposase accessible chromatin 
followed by next generation sequencing, and the ATAC-seq experiment can provide 
genome-wide profiles of accessible chromatin and nucleosomes positions through the 
ATAC-seq data analysis. The working principle of ATAC-seq is by loading the Tn5 
transposase and illumine sequencing primers can be inserted into the open chromatin 
sites of the whole genome for each cell, the reads after sequencing can be mapped to 
the reference genome and mark the open chromatin sites.  
The genetics of OA is complex. It has very small proportion of genetic 
heritability in knee OA and currently there is no typical susceptible single gene 
associated with it (Fernandez-Moreno et al., 2008; Johnson & Hunter, 2014). Therefore, 
the polygenic nature of OA suggests that epigenetic components may be an important 
factor in the progression of the disease. However very little epigenetic landscape of OA 
is known. There have been some reports on the genome-wide DNA methylation studies 
(Alvarez-Garcia et al., 2016), one of which showed majority (69%) of the differentially 
methylated regions are hypo-methylated and are found at gene enhancers (Jeffries et 
al., 2014). Still, relatively few DNA methylation alteration was found in OA diseased 
tissues, despite many differential expressed genes. Our previous study by 
characterizing the genome-wide DNA methylation changing in OA indicated that HOX 
genes activated, revealing a self-renewal capacity in diseased tissue (Y. Zhang et al., 
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2016).  Furthermore, at the chromatin level, there is no genome-wide studies. Here, I 
sought to investigate genome-wide variations of OA at the chromatin level. This study 
marks the first application of ATAC-seq on clinically relevant hard tissue and showed 
how accessible chromatin profiling can provide comprehensive epigenetic information 
to understand the pathogenesis of a disease.   
 
3.2 Materials and methods 
3.2.1 ATAC-seq data processing, peak calling and quality assessment 
An ATAC-seq data processing pipeline for read mapping, peak calling, signal 
track generation, and quality control was implemented (Lee et al., 2016) (Figure 3-1). 
Briefly, fastq files for all patients were grouped by tissue compartment (oLT or iMT) 
and input into the pipeline separately, with parameters –true_rep –no_idr. Reads were 
mapped to the hg38 reference genome. Peaks were called by macs2 with default 
parameters in the pipeline. Basic sequencing information and library quality metrics are 
listed in Table 2-3.  
NucleoATAC was applied to infer genome-wide nucleosome positions and 
occupancy from the ATAC-seq data (Schep et al., 2015). Briefly, NucleoATAC were 
run for oLT and iMT separately with default parameters, using bam files merging from 
all patients as input, and the outputted nucleoatac_signal.bedgraph were used for 
aggregated plot around TSS.  
Previously annotated DNase I Hypersensitive Sites (DHS) were used to assess 
the quality of our libraries. Briefly, a set of DHS defined in Roadmap Epigenomics 
Project (Boyle et al., 2008) were downloaded 
(http://egg2.wustl.edu/roadmap/web_portal/DNase_reg.html) and lifted over from 
hg19 to hg38 using UCSC liftOver tool (Kent et al., 2002) (refer as Roadmap DHS 
thereafter). For each library, I calculated the ratio of reads that fall within Roadmap 
DHS versus randomly chosen genomic regions of the same total size (DHS enrichment 
score). It is noted that the DHS enrichment score is in good correlation with enrichment 
qPCR for GAPDH (Figure 2-6). 
 
3.2.2 Defining a set of unified accessible chromatin regions 
Peaks from all 16 libraries were pooled and those that are within 300 bp were 
merged, resulting in 615,454 merged raw peaks. Reads fall in raw peak regions were 
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counted for individual samples using bedtools v2.27.0 (Quinlan & Hall, 2010). Read 
counts were normalized as count-per-million (CPM) based on relative log expression 
normalization implemented in edgeR v3.18.1 (McCarthy et al., 2012; Robinson et al., 
2010). In the end, I defined a set robust peaks (n=109,215) with  2 CPM in at least 6 
oLT or 6 iMT samples for all downstream analyses. 
 
3.2.3 Peak annotation and differentially accessible peak identification 
Peaks were annotated as promoters or enhancers based on their intersection with 
promoter or enhancer as defined in Roadmap DHS (Bernstein et al., 2010). Noted that 
a peak (n=1,693) was preferentially annotated as a promoter if it intersects both a 
promoter and an enhancer DHS, in general, those proximal enhancers are epigenetically 
closed to promoters. Differentially accessible peaks between damaged (i.e. iMT) and 
intact (i.e. oLT) tissues were identified using edgeR (McCarthy et al., 2012; Robinson 
et al., 2010). Briefly, reads were normalized by library size and DHS enrichment score 
of each sample were incorporated as continuous covariates in the design matrix of the 
generalized linear model implemented in edgeR (McCarthy et al., 2012; Robinson et 
al., 2010). The Benjamini-Hochberg adjusted p-values (i.e. false discovery rate, FDR) 
was taken to measure the extent of differential accessibility. A cutoff of FDR  0.05 
was used to define differentially accessible peaks. 
 
3.2.4 Processing of OA associated SNPs 
GWAS lead SNPs of OA were obtained from GWASdb v2 (as of 16 Sep 2017) 
(M. J. Li et al., 2016), NHGRI-EBI GWAS Catalog (as of 16 Sep 2017) (MacArthur et 
al., 2017), and a recent study (Zengini et al., 2017). SNPs in linkage disequilibrium 
with these lead SNPs (i.e. proxy SNPs with r2 > 0.5 and distance limit of 500kb in any 
three population panels of the 1000 Genomes Project pilot 1 data) were obtained from 
SNAP database (A. D. Johnson et al., 2008), resulting in 8,973 GWAS SNPs associated 
with OA. As a negative control, GWAS SNPs associated with Parkinson’s disease were 
obtained the same way from NHGRI-EBI GWAS Catalog. Coordinates for these SNPs 
in hg38 were obtained from dbSNP Build 150. 
 
3.2.5 Definition of cell type-specific enhancers  
Bed files for enhancer clusters with coordinated activity in 127 epigenomes, as 
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well as the density of clusters per cell type, were obtained from online database 
(http://egg2.wustl.edu/roadmap/web_portal/DNase_reg.html). DNase I regions 
selected with p < 1 × 10–2, lifted over from hg19 to hg38 using UCSC liftOver tool. For 
each cell type, clusters with two-fold density than average (across all cell types) were 
defined as specific and pooled. 
 
3.2.6 Enrichment analysis for differentially accessible peaks 
Fisher’s exact test were applied to assess the enrichment for the cell type-
specific enhancers. Briefly, differentially accessible peaks (FDR ≤ 0.05) were 
compared to all peaks, and same number of randomly selected peaks were used as a 
control.  Permutation of peaks as control were done 25 times. 
 
3.2.7 Linking enhancer peaks to their potential target genes 
A promoter peak is assigned to a gene if it intersects with the transcription start 
sites (TSS) of its transcript as defined in the FANTOM CAGE associated transcriptome 
(Hon et al., 2017). I noted that a promoter peak might be associated with multiple genes. 
An enhancer peak is defined as linked to a target gene if it overlaps an expression 
quantitative trait loci (eQTL) of the corresponding gene (GTEx V7, in any tissues with 
p < 1 × 10–5) (Consortium, 2015), or is supported by putative enhancer-promoter 
linkage predicted by JEME method (http://yiplab.cse.cuhk.edu.hk/jeme/based) on 
FANTOM5 and Roadmap Epigenomics Project data (Cao et al., 2017).  
 
3.2.8 Integration with publicly available transcriptome data 
 An RNA-seq dataset (ArrayExpress E-MTAB-4304) from an independent OA 
patient cohort was reanalyzed, in which the RNA was extracted from cartilage tissues 
of both iMT and oLT for 8 patients (Dunn et al., 2016). Read counts on transcripts were 
estimated by Kallisto v0.43.1 (Bray et al., 2016) using default parameters on FANTOM 
CAGE associated transcriptome (Hon et al., 2017). Estimated read counts of a gene, 
defined as the sum of the estimated read counts of its associated transcripts, were used 
as the input for differential gene expression analysis using edgeR v3.18.1. In total, 
3,293 genes were defined as significantly differentially expressed between iMT and 
oLT (FDR ≤ 0.05). A gene is defined as “consistently dysregulated both at the 
epigenomic and transcriptomic levels” when it is upregulated (or downregulated) in 
RNA-seq with more (or less) accessible promoters or enhancers in ATAC-seq (n= 371). 
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3.2.9 Gene ontology analysis 
R (version 3.4.0) was used for performing statistical analyses via an integrated 
development environment (IDE), Rstudio (version 1.0.143). R/Bioconductor project 
packages edgeR (version 3.18.1) (Robinson et al., 2010), ChIPseeker (version 1.12.0) 
(Yu et al., 2015) were utilized. More R packages used in the data processing, ggplot2 
(version 2.2.1), dplyr (version 0.5.0), limma (version 3.32.2), data.table (version 
1.10.4), magrittr (version 1.5) TxDb.Hsapiens.UCSC.hg38.knownGene (version 3.4.0), 
rafalib (version 1.0.0), piper (version 0.6.1.3), reshape2 (version 1.4.2).  
Linux command line based tools used for data processing, HOMER (version 
4.9), bedtools (version 2.26.0), macs2 (version 2.1.1.20160309) 
 
3.2.10 Statistics  
In the differential ATAC-seq peak assay, ANOVA (one way analysis of 
variance) test was performed, with a BH multiple test correction, the adjusted p-value 
(FDR) ≤ 0.05 was considered significant. HOMER de novo motifs assay, p-value < 1e-
15 was considered significant. Enrichr GO/pathway analyses, p-value < 0.01 was 
considered significant. RedeR network assay, p-value < 0.001 was considered 
significant.  
 
3.3 Results and Discussion 
3.3.1 ATAC-seq data processing, peak calling and quality assessment 
When applied nucleoATAC to infer genome-wide nucleosome occupancy and 
positioning from ATAC-seq data 35, it is shown similar aggregated signals around 
transcription start sites (TSS) for both oLT and iMT libraries, corresponding to –2, –1, 
+1, +2, +3 nucleosomes as well as nucleosome depletion region at upstream of TSS 
(Figure 3-2). Thus, it is concluded that the ATAC-seq libraries had good and 
indistinguishable quality between oLT and iMT regions. 
3.3.2 Accessible chromatin landscape highlights potential enhancers and their target 
genes relevant to OA  
Based on the 16 ATAC-seq libraries, I identified a set of unified accessible 
chromatin regions across all samples (n=109,215 robust peaks, Methods); 77,655 
(71.1%) of which were annotated as enhancers and 18,410 (16.9%) as promoters 
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(Figure 3-3) based on Roadmap DHS annotations (Methods). To assess the relevance 
of these peaks to OA, these peaks were intersected against OA GWAS (Single 
Nucleotide Polymorphisms) SNPs and OA DML datasets. 149 peaks (31 promoters and 
101 enhancers) were found overlapping with OA-associated GWAS SNPs and 2,508 
peaks (595 promoters and 1,715 enhancers) overlapping with OA DML. The fact that 
majority of these overlapping peaks are enhancers, along with the notion that many 
disease-associated noncoding variants reside in enhancers (Corradin & Scacheri, 2014; 
Farh et al., 2015), suggest the dysregulation of enhancer might play a role in OA 
pathogenesis. To further characterize these potentially OA-relevant enhancers, public 
resources (Cao et al., 2017; Lonsdale et al., 2013) to predict their target genes (Methods) 
were utilized. Enhancers that overlap OA GWAS SNPs and OA DML were identified, 
as well as their predicted target genes, representing candidates of dysregulated 
transcriptional network during OA pathogenesis. The list includes previously identified 
OA associated genes, such as FGFR3 (Tang et al., 2016; S. Zhou et al., 2016) (its 
enhancer overlaps an OA GWAS SNP, Figure 3-4 up) and PTEN (Iwasa et al., 2014) 
(its predicted enhancer overlaps with an OA DML, Figure 3-4 down), thus validating 
this approach.  
It has been verified 7 OA associated SNPs (rs10851630, rs10851631, 
rs10851632, rs12905608, rs12910752, rs4238326, and rs35246600) reside in 3 
chondrocyte accessible enhancers of the predicted target gene ALDH1A2. rs4646626 
has previously been identified as a suggestive OA risk locus (p = 9 × 10–6, (Zeggini et 
al., 2012)), for which it is found two proxy SNPs (rs10851632 and rs12905608), 
predicted to target the ALDH1A2 gene, hitting the accessible enhancer region 
(chr15:57949887-57950974 and chr15:58021340-58022482, respectively) in the 
samples. Since ALDH1A2 is inactivated in prechondrogenic mesenchyme during the 
cartilage development (Hoffman et al., 2006), these SNPs may contribute to OA 
through disrupting the enhancer of ALDH1A2 and inappropriately activating a cell 
differentiation pathway. Consistently, OA genetic risk variants in ALDH1A2 locus has 
also been functionally characterized in a recent study (Shepherd et al., 2018).   
In addition, I identified several aberrantly methylated enhancers that may be 
associated with OA. The example is cg09221159 within the enhancer for PTEN gene 
which is hypomethylated in the damaged cartilage (Zhang et al., 2016). PTEN is 
involved in the positive regulation of the apoptotic signaling pathway and its activation 
is consistent with the notion that chondrocyte apoptosis may contribute to the failure in 
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appropriately maintaining the cartilage. Thus, my analyses show that the chromatin 
accessibility map can provide an additional layer of evidence for determining which 
loci, especially those in the non-coding regions, are associated with OA, which may 
have been ignored in previous studies.   
Therefore, this study provides an accessible chromatin landscape of cartilage 
tissue for better interpretation of other genetic and epigenomic data relevant to OA and 
other skeletomuscular disease, although caution should be taken since public data from 
many populations are involved in the integrative analysis while our ATAC-seq dataset 
is acquired from the Japanese population. 
 
3.3.3 Identification of differentially accessible enhancers in OA 
To compare the accessible chromatin landscape between the intact (oLT) and 
the damaged (iMT) tissues, principal component analysis was performed on the peak 
signals across the 16 samples. The first principal component (41.37% of variance) can 
be attributed to tissue damage variations (i.e. oLT versus iMT), while the second 
principal component (16.03% of variance) can be attributed to patient-to-patient 
variations (Figure 3-5). This observation suggests the accessible chromatin landscapes 
of damaged and intact tissues are readily distinguishable from each other, despite the 
variations among individual patients.   
To identify the chromatin signatures relevant to OA, differential accessibility 
analysis was performed between oLT and iMT using edgeR (Robinson et al., 2010). 
The Benjamini-Hochberg adjusted p-values (i.e. false discovery rate, FDR) was taken 
to measure the extent of differential accessibility with the percentage of the annotation 
(Figure 3-6), the peaks with smaller FDR (i.e. more confident to be differentially 
accessible) contain more enhancer peaks, suggesting the enhancers are more likely to 
be dysregulated in OA cartilage. Significant differentially accessible peaks were 
determined with FDR  0.05. Out of the 4,450 differentially accessible peaks, 1,565 are 
more accessible and 2,885 are less accessible in the damaged tissues compared to the 
intact tissues (Figure 3-7, Figure 3-8). The identified differentially accessible peaks are 
generally consistent among patients (Figure 3-9).  Majority (85.3%) of these 
differentially accessible peaks are enhancers and only 7.6 % are promoters. It is noted 
that the promoter accessibility of SOX11 and RGR are altered in the OA damaged 
tissues (more accessible for SOX11 and less accessible for RGR, Figure 3-8), which are 
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consistent with the previous findings that they are up- and down-regulated in OA 
damaged tissues, respectively (Chou et al., 2015). Moreover, the differentially 
accessible enhancers (FDR  0.05) overlapping either OA GWAS SNP (n = 5; from 4 
independent loci) or OA DML (n = 16, concordant in direction) are summarized in 
Table 3-1 and Table 3-2, respectively.   
Majority of the differentially accessible peaks are enhancers, which are known 
to regulate transcription. Cell type-specific enhancers largely drive the transcriptional 
program required to carry out specific functions for each cell type (Heinz et al., 2015) 
and their dysregulation may lead to diseases (Kron et al., 2014). To assess the cell type 
specificity of the differentially accessible enhancers identified in this study, I examined 
their enrichment of cell type-specific enhancers of 125 cell types defined by the 
Roadmap Epigenomics Project (Bernstein et al., 2010). These differential accessible 
enhancers are highly enriched for enhancers were found that are specific to bone-related 
cell types in damaged tissues (e.g. chondrocyte and osteoblast), as well as mesenchymal 
stem cells (MSC) and fibroblasts, which have been reported to have similar profiles to 
MSC (Hematti, 2012) (Figure 3-10).  
In summary, the differential accessible chromatin regions identified in this 
study are enriched in OA-relevant enhancers supported by multiple genetic and 
epigenomic evidence. These differentially accessible enhancers and their predicted 
target genes could be used for prioritization of candidate genes to be tested for studying 
OA disease progression.  
 
3.3.4 Motif enrichment analysis reveals transcription factors relevant to OA 
In order to gain more insights into which regulatory pathways may be 
dysregulated in OA, next the enrichment of transcription factor binding motifs in the 
differentially accessible regions were examined. Enrichment analyses were performed 
separately for the regions that are significantly more or less accessible in the damaged 
tissues, using all accessible regions as background. Transcription factors with 
significantly enriched motifs are summarized (Figure 3-10A), and their binding 
prediction in robust peaks are listed (Figure 3-10B). It is noted that most of these 
transcription factors belong to ETS and bZIP family; many of which are known to 
regulate genes involved in bone or cartilage development, including AP-1 (Vincenti & 
Brinckerhoff, 2002), CEBP (Okuma et al., 2015), MafK (Hong et al., 2011), STAT3 
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(Hayashi et al., 2015), and ERG (Iwamoto et al., 2001; Iwamoto et al., 2007). Moreover, 
it has been previously proposed that ETS-1 may be involved in OA based on the DML 
study (Zhang et al., 2016).  
The transcription factor Jun-AP1, which is enriched in the more accessible 
regions of the damaged tissues, is known to regulate chondrocyte hypertrophic 
morphology, which contributes to longitudinal bone growth, consistent with the notion 
of endochondral ossification (He et al., 2016). A recent study showed injection of 
adipose-derived stromal cells overexpressing an AP-1 family transcription factor Fra-1 
can inhibit OA progression in mice (Schwabe et al., 2016). Consistently, in this ATAC-
seq analysis, other members of AP-1 family (e.g. BATF, FOSL2) also showed 
enrichment in differentially accessible regions.  
Taken together, the motif enrichment analysis of the differentially accessible 
regions in the damaged tissues is consistent with the hypothesis that the transcriptional 
program for chondrocyte differentiation may be disrupted during OA progression, and 
suggests that cell type-specific enhancers may be dysregulated through the ETS and 
bZIP family transcription factors. 
 
3.3.5 Integrative transcriptomics and epigenomics analysis reveals pathways involved 
in OA 
To evaluate the effects of the dysregulated regulatory regions on gene 
expression in OA, the RNA-seq dataset from a different cohort that used the same 
disease model (i.e. oLT vs. iMT) (Dunn et al., 2016) were reanalyzed and integrated it 
with the differentially accessible regions identified in this study (Figure 3-11). Firstly, 
the dysregulated regulatory regions have detectable effects on the gene expression were 
verified; the genes with more accessible promoters or enhancers have significantly 
higher expression fold-changes between oLT and iMT (p < 0.001, Student’s t-test) than 
the ones with less accessible promoters or enhancers (Figure 3-12). To further 
investigate the congruence between these transcriptomic and epigenomic changes, the 
significant differentially expressed genes (n=3,293, FDR  0.05) were overlapped onto 
the genes with differentially accessible promoters (n=255) or enhancers (n=2,406) 
(Figure 3-13). The overlaps are statistically significant (p < 0.001 in both promoters 
and enhancers, Fisher’s exact test), and further demonstrate the chromatin accessibility 
dataset from this study is generally consistent with the transcriptomic dataset. As a 
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result, 371 genes were identified that are consistently dysregulated both at the 
epigenomic and transcriptomic levels, representing a shortlist of OA-related candidate 
genes supported by multiple lines of evidence (Figure 3-13, Table 3-3 and Table 3-4).   
It was found that BMPR1B (bone morphogenetic protein receptor type 1B) is 
upregulated and both its promoter and enhancer are more accessible in the damaged 
tissue. Its activation is consistent with the ossification pathway activation, since it 
encodes a transmembrane serine kinase that binds to BMP ligands that positively 
regulate endochondral ossification and abnormal chondrogenesis (J. Li & Dong, 2016; 
Yoon et al., 2005). Consistently, an osteoblast marker gene MSX2 (Msh Homeobox 2) 
involved in promoting osteoblast differentiation (Cheng et al., 2003; Matsubara et al., 
2008), is upregulated and both its promoter and enhancer are more accessible in the 
damaged tissue, suggesting the osteoblast differentiation may be activated in OA. 
Furthermore, it was found ROR2 (receptor tyrosine kinase like orphan receptor 2) is 
down regulated and its enhancers are less accessible in the damaged samples. Since it 
is required for cartilage development (Dickinson & Hollander, 2017; Schille et al., 
2016), it suggests that the normal chondrocyte development and cartilage formation 
may be compromised in OA. Consistently, I have also determined FGFR2 and STAT1, 
which are known to inhibit chondrocyte proliferation (Karuppaiah et al., 2016), are 
upregulated.  
To elucidate the biological pathways dysregulated in OA, the enrichment of 
gene ontology (GO) terms of the 371 OA-related candidate genes using enrichr 
(Kuleshov et al., 2016) (Figure 3-14, top 30 terms listed) was examined. Overall, I 
observed the enrichment of GO terms related to cell fate and differentiation, including 
MSC differentiation, ossification and bone development (Figure 3-14). In the ‘positive 
regulation of ossification pathway’, two genes were identified to be more accessible 
and upregulated: SOX11 (only the promoter is more accessible) and WNT5A (both the 
promoter and the enhancer are more accessible). It has been shown that WNT5A protein 
can induce matrix metalloproteinase production and cartilage destruction (Huang et al., 
2017), and its upregulation is consistent with ossification being an important process 
and signature of OA progression. Other susceptible genes and pathways that support 
the ossification during OA from this analysis include LRP5, FGFR2 and BMPR1B in 
the endochondral bone morphogenesis pathway, which have been reported as OA 
associated genes previously(den Hollander et al., 2014; Ellman et al., 2013; Fernández-
Tajes et al., 2014; Papathanasiou et al., 2010; Rushton et al., 2014; Wu et al., 2016). In 
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conclusion, the integrative analysis of ATAC-seq and publicly available RNA-seq 
datasets indicates that dysregulated chondrocyte differentiation and endochondral 
ossification are associated with OA progression.  
 
3.4 Summary 
The strategy of integrating the epigenomic data of clinically relevant tissues 
with the publicly available genetic and transcriptomic data allowed bettering 
understanding how the identified loci may contribute to OA pathogenesis. Most of these 
accessible chromatin regions are enhancers and the large scale public datasets enable 
like them to their putative target genes. Previous studies have suggested the potential 
role of OA-associated epigenetic changes within enhancers in disease pathogenesis 
(den Hollander & Meulenbelt, 2015; van Meurs, 2017). With this enhancer-gene map 
in chondrocyte, it can now better interpret the previously identified OA GWAS SNPs 
or OA differential methylated loci located lie outside of the coding regions.  
In general, the differential enhancer analysis shows MSC, chondrocyte and 
osteoblast-specific enhancers are dysregulated in the damaged tissues. Furthermore, 
motif enrichment analysis of differentially accessible loci has identified many 
dysregulated transcription factors, the functions of which are known to be in 
chondrocyte development regulation. 
In the integrative analysis of ATAC-seq and RNA-seq, many dysregulated 
genes related to lineage differentiation of MSC pathways were observed.  
The pathogenesis for OA is not yet fully understood, despite multiple genes and 
pathways that have been characterized to be dysregulated (Dunn et al., 2016; Shen et 
al., 2017; Steinberg et al., 2017; Uhalte et al., 2017; Usami et al., 2016). In this study, 
by integrating clinically relevant epigenomic data with genetic and transcriptomic data, 
it provides multiple lines of evidence supporting a number OA candidate genes and 
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pathways that may be crucial to OA pathogenesis, which could potentially be used for 
clinical diagnostic or as therapeutic targets.  
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Table 3-1 Differentially accessible enhancers overlapping with OA GWAS SNPs. 
Enhancer peak ID Proxy SNP ID Lead SNP ID r2 
GWAS P 
value 
Phenotype Population GWAS literature 
log2(fold 
change) 
FDR 
Predicted 
target 
gene(s) 
chr7:32611048-
32612186 
rs10807862 rs7805536 0.8 4.4×10-8 OA  EUR 
(Zeggini et al., 
2012) 
-0.96 0.01 
ZNRF2P1; 
DPY19L1P1; 
AVL9; LSM5 
chr7:32616344-
32617105 
rs10951345 rs7805536 0.8 4.4×10-8 OA  EUR 
(Zeggini et al., 
2012) 
-0.77 0.03 
DPY19L1P1; 
AVL9 
chr10:119370132-
119371726 
rs17098787 rs11198893 0.9 9.0×10-6 
OA (knee 
and hip) 
EUR 
(Panoutsopoulou 
et al., 2011) 
-0.59 0.02 
RP11-
215A21.2 
chr7:44238166-
44238952 
rs67391165 rs3757837 1.0 8.0×10-10 OA (hip) EUR 
(Evangelou et al., 
2014) 
0.62 0.03 MYL7; YKT6 
chr8:125503356-
125504061 
rs7832357 rs4512391 1.0 1.1×10-6 
OA (knee 
and hip) 
EUR 
(Panoutsopoulou 
et al., 2011) 
-0.54 0.04 NA 
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Table 3-2 Differentially accessible enhancers overlapping with OA DMLs. 
Enhancer peak ID DML Delta beta* 
Log2 (fold 
change) 
FDR 
Predicted 
target gene(s) 
chr1:19398124-19398841 cg06360604 -0.177 1.194 0.003 
AKR7A2; AKR7A3; CAPZB; 
PQLC2 
chr16:66511371-66512170 cg02934719 -0.168 0.827 0.021 BEAN1; TK2 
chr11:74025533-74026295 cg01117339 -0.164 0.623 0.037 COA4; RAB6A; UCP2 
chr1:85606965-85607684 cg00418071 -0.157 1.214 0.001 CYR61; DDAH1; ZNHIT6; SYDE2 
chr4:158809913-158811140 cg11637968 -0.218 0.878 0.032 
ETFDH; FAM198B; FNIP2; PPID; 
C4orf46 
chr5:32767956-32768626 cg26647771 -0.198 0.924 0.010 GOLPH3; NPR3; TARS 
chr1:226708432-226710048 cg04503570 -0.166 0.500 0.046 PSEN2 
chr2:1720779-1722443 cg08216099 -0.193 0.732 0.016 PXDN 
chr10:119523073-119524950 cg18591136 -0.152 0.508 0.040 RGS10 
chr6:168412123-168412714 cg26379705 -0.174 0.736 0.009 SMOC2 
chr6:146850220-146851275 cg18291422 -0.184 0.960 0.012 STXBP5 
chr8:81688679-81689538 cg04491064 0.164 -0.959 0.046 CHMP4C 
chr12:124700740-124701544 cg04658679 0.160 -0.514 0.030 FAM101A; UBC 
chr4:26412447-26413348 cg22992279 0.159 -0.737 0.028 RBPJ 
chr11:35344856-35345647 cg13971030 0.157 -0.656 0.038 SLC1A2 
chr12:132846887-132848225 cg21232015 0.151 -0.615 0.038 
ZNF10; ZNF268; ZNF605; 
ZNF84; GOLGA3; ANKLE2; CHFR 
* Positive or negative delta beta indicates hypermethylation or hypomethylation in iMT, respectively. 
  
 44 
Table 3-3 OA associated genes enriched in top 30 GO terms. 
Term GO term ID Overlap P.value % enhrichment 
Differential gene enriched in terms 
pro  enh  pro&enh 
positive regulation of TRAIL-activated apoptotic 
signaling pathway 
GO:1903984 2/6 0.005 33.3 PMAIP1 THBS1  
positive regulation of mesenchymal stem cell 
proliferation 
GO:1902462 2/6 0.005 33.3 HMGA2;SOX11  
negative regulation of collateral sprouting of 
intact axon in response to injury 
GO:0048685 3/9 0.000 33.3 DCC PTPRS;RTN4RL1 
mesenchymal cell fate commitment GO:0014030 2/6 0.005 33.3 HMGA2 FGFR2  
mesenchymal cell differentiation involved in 
salivary gland development 
GO:0060692 2/6 0.005 33.3 HMGA2 FGFR2  
mesenchymal cell differentiation GO:0048762 2/6 0.005 33.3 HMGA2 FGFR2  
embryonic ectodermal digestive tract 
morphogenesis 
GO:0048613 3/9 0.000 33.3 SOX11 FOXF1;FGFR2  
collateral sprouting of intact axon in response to 
injury 
GO:0048673 2/6 0.005 33.3  RTN4RL1;BDNF 
choline catabolic process GO:0042426 2/6 0.005 33.3  SLC44A1;CHDH 
cardiac endothelial to mesenchymal transition GO:0140074 2/6 0.005 33.3 HMGA2 FGFR2  
positive regulation of metanephric cap 
mesenchymal cell proliferation 
GO:0090096 3/10 0.001 30.0 CHRD LRP5;FGFR2  
positive regulation of mesenchymal cell 
proliferation involved in lung development 
GO:2000792 3/10 0.001 30.0 CHRD LRP5;FGFR2  
post-embryonic limb morphogenesis GO:0035127 2/7 0.007 28.6  TBX4 BMPR1B 
negative regulation of optical nerve axon 
regeneration 
GO:1905592 2/7 0.007 28.6  PTPRS;RTN4RL1 
lens fiber cell development GO:0070307 2/7 0.007 28.6 WNT5B MAF  
positive regulation of mesenchymal cell 
proliferation involved in ureter development 
GO:2000729 3/11 0.001 27.3 CHRD LRP5;FGFR2  
positive regulation of ossification GO:0045778 2/8 0.009 25.0 SOX11  WNT5A 
positive regulation of cilium movement GO:0003353 2/8 0.009 25.0  RPS19;ETS1  
positive regulation of actin filament-based 
movement 
GO:1903116 2/8 0.009 25.0  RPS19;ETS1  
hindlimb morphogenesis GO:0035137 2/8 0.009 25.0  TBX4 BMPR1B 
hexose transmembrane transport GO:0035428 2/8 0.009 25.0  SLC2A12;SLC2A5 
fat body development GO:0007503 2/8 0.009 25.0  ZNF516;LRP5  
endochondral bone morphogenesis GO:0060350 3/13 0.002 23.1  LRP5;FGFR2 BMPR1B 
post-embryonic camera-type eye 
morphogenesis 
GO:0048597 2/9 0.011 22.2 TENM3 IFT122  
positive regulation of extrathymic T cell 
differentiation 
GO:0033090 2/9 0.011 22.2 ZMIZ1;PRDM1  
positive regulation of cellular component 
movement 
GO:0051272 2/9 0.011 22.2  RPS19;ETS1  
negative regulation of dendritic spine 
development 
GO:0061000 2/9 0.011 22.2 DCC PTPRS  
fat pad development GO:0060613 2/9 0.011 22.2  ZNF516;LRP5  
establishment of epithelial cell apical/basal 
polarity involved in camera-type eye 
morphogenesis 
GO:0003412 2/9 0.011 22.2 TENM3 IFT122  
adipose tissue development GO:0060612 2/9 0.011 22.2   ZNF516;LRP5   
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Table 3-4 Differential genes detected by RNA-seq and ATAC-seq. 
 
geneName geneID geneType logFC.rna logCPM.rna FDR.rna venn_diagram 
ZNF775 ENSG00000196456 protein_coding -0.418 3.309 0.009 rna|__na|enhancer 
ZNF740 ENSG00000139651 protein_coding -0.337 4.624 0.016 rna|__na|enhancer 
ZNF662 ENSG00000182983 protein_coding -0.367 3.310 0.042 rna|__na|enhancer 
ZNF648 ENSG00000179930 protein_coding -1.141 0.848 0.016 rna|__na|enhancer 
ZNF592 ENSG00000166716 protein_coding -0.283 4.926 0.031 rna|__na|enhancer 
ZNF516 ENSG00000101493 protein_coding -0.695 2.375 0.004 rna|__na|enhancer 
ZNF273 ENSG00000198039 protein_coding -0.473 2.705 0.016 rna|__na|enhancer 
ZNF107 ENSG00000196247 protein_coding -0.456 3.826 0.011 rna|__na|enhancer 
ZMIZ1 ENSG00000108175 protein_coding -0.732 7.696 0.007 rna|promoter|__na 
ZIC4 ENSG00000174963 protein_coding 1.260 0.236 0.019 rna|promoter|__na 
ZIC1 ENSG00000152977 protein_coding 0.810 2.676 0.025 rna|promoter|__na 
ZDHHC2 ENSG00000104219 protein_coding 0.641 4.820 0.008 rna|__na|enhancer 
YWHAZ ENSG00000164924 protein_coding 0.455 7.892 0.004 rna|__na|enhancer 
YKT6 ENSG00000106636 protein_coding 0.244 6.147 0.024 rna|__na|enhancer 
YEATS4 ENSG00000127337 protein_coding 0.442 2.921 0.014 rna|__na|enhancer 
WWP2 ENSG00000198373 protein_coding -0.761 9.389 0.005 rna|__na|enhancer 
WNT9A ENSG00000143816 protein_coding 0.800 2.292 0.029 rna|promoter|__na 
WNT5B ENSG00000111186 protein_coding 0.791 3.189 0.025 rna|promoter|__na 
WNT5A ENSG00000114251 protein_coding 1.247 0.766 0.033 rna|promoter|enhancer 
WNK2 ENSG00000165238 protein_coding -1.553 3.500 0.005 rna|__na|enhancer 
VWC2 ENSG00000188730 protein_coding 1.203 2.751 0.005 rna|promoter|__na 
VRK3 ENSG00000105053 protein_coding -0.437 2.917 0.009 rna|__na|enhancer 
VPS53 ENSG00000141252 protein_coding -0.245 3.957 0.037 rna|__na|enhancer 
VIT ENSG00000205221 protein_coding -1.830 6.609 0.014 rna|__na|enhancer 
USP2 ENSG00000036672 protein_coding 0.616 1.241 0.039 rna|__na|enhancer 
UROD ENSG00000126088 protein_coding 0.267 4.831 0.030 rna|__na|enhancer 
UBLCP1 ENSG00000164332 protein_coding 0.534 4.288 0.005 rna|__na|enhancer 
UBL3 ENSG00000122042 protein_coding 0.473 5.783 0.004 rna|__na|enhancer 
UBAP1L ENSG00000246922 protein_coding -0.890 1.785 0.037 rna|__na|enhancer 
UBAC2 ENSG00000134882 protein_coding 0.648 5.645 0.003 rna|__na|enhancer 
TXNDC5 ENSG00000239264 protein_coding 0.259 7.772 0.018 rna|__na|enhancer 
TUBA1A ENSG00000167552 protein_coding 0.615 6.885 0.040 rna|__na|enhancer 
TTC28 ENSG00000100154 protein_coding -0.434 4.524 0.011 rna|__na|enhancer 
TSPYL5 ENSG00000180543 protein_coding -0.286 5.176 0.017 rna|__na|enhancer 
TSEN15 ENSG00000198860 protein_coding 0.369 4.644 0.014 rna|__na|enhancer 
TSC22D1 ENSG00000102804 protein_coding -0.502 9.713 0.019 rna|__na|enhancer 
TRIM36 ENSG00000152503 protein_coding 2.298 1.545 0.008 rna|promoter|__na 
TRANK1 ENSG00000168016 protein_coding -0.588 3.316 0.019 rna|__na|enhancer 
TRAF1 ENSG00000056558 protein_coding -0.747 3.936 0.004 rna|__na|enhancer 
TOM1L1 ENSG00000141198 protein_coding 1.610 2.373 0.005 rna|promoter|__na 
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TNS3 ENSG00000136205 protein_coding -0.567 8.527 0.005 rna|__na|enhancer 
TMEM8B ENSG00000137103 protein_coding -0.603 4.156 0.003 rna|__na|enhancer 
TMEM59L ENSG00000105696 protein_coding 2.220 1.995 0.012 rna|promoter|__na 
TMEM37 ENSG00000171227 protein_coding -0.844 1.189 0.042 rna|__na|enhancer 
TMEM14B ENSG00000137210 protein_coding 0.312 5.106 0.046 rna|__na|enhancer 
TMCO3 ENSG00000150403 protein_coding 0.355 7.058 0.013 rna|__na|enhancer 
THBS1 ENSG00000137801 protein_coding -0.577 9.426 0.037 rna|__na|enhancer 
TGFBI ENSG00000120708 protein_coding 1.023 9.654 0.035 rna|__na|enhancer 
TEX30 ENSG00000151287 protein_coding 0.581 1.704 0.039 rna|__na|enhancer 
TENM3 ENSG00000218336 protein_coding 1.584 2.780 0.008 rna|promoter|__na 
TEN1 ENSG00000257949 protein_coding 0.404 2.287 0.024 rna|__na|enhancer 
TBX4 ENSG00000121075 protein_coding -0.810 4.995 0.010 rna|__na|enhancer 
TBPL1 ENSG00000028839 protein_coding 0.439 3.503 0.014 rna|__na|enhancer 
TBL1X ENSG00000101849 protein_coding -0.383 3.556 0.027 rna|__na|enhancer 
TATDN3 ENSG00000203705 protein_coding 0.352 2.778 0.021 rna|__na|enhancer 
TATDN1 ENSG00000147687 protein_coding 0.315 3.777 0.041 rna|__na|enhancer 
TARS ENSG00000113407 protein_coding 0.304 5.463 0.033 rna|__na|enhancer 
STK32A ENSG00000169302 protein_coding -0.718 4.777 0.034 rna|__na|enhancer 
ST6GALNAC5 ENSG00000117069 protein_coding 1.545 4.163 0.004 rna|promoter|__na 
ST6GAL2 ENSG00000144057 protein_coding 1.465 0.758 0.048 rna|promoter|__na 
ST3GAL6 ENSG00000064225 protein_coding -0.733 2.740 0.020 rna|__na|enhancer 
SSR1 ENSG00000124783 protein_coding 0.219 7.768 0.047 rna|__na|enhancer 
SPTLC3 ENSG00000172296 protein_coding 0.417 2.646 0.043 rna|__na|enhancer 
SPRED2 ENSG00000198369 protein_coding -0.372 4.693 0.024 rna|__na|enhancer 
SPECC1 ENSG00000128487 protein_coding 0.758 5.856 0.009 rna|__na|enhancer 
SPATA6 ENSG00000132122 protein_coding -0.412 2.789 0.047 rna|__na|enhancer 
SOX11 ENSG00000176887 protein_coding 2.471 2.233 0.022 rna|promoter|__na 
SOCS5 ENSG00000171150 protein_coding 0.346 5.023 0.035 rna|__na|enhancer 
SNRNP25 ENSG00000161981 protein_coding 0.309 3.221 0.042 rna|__na|enhancer 
SMIM5 ENSG00000204323 protein_coding 0.881 2.869 0.007 rna|__na|enhancer 
SLC7A2 ENSG00000003989 protein_coding 1.216 7.892 0.011 rna|__na|enhancer 
SLC44A1 ENSG00000070214 protein_coding 0.290 5.270 0.021 rna|__na|enhancer 
SLC43A3 ENSG00000134802 protein_coding -0.668 6.480 0.003 rna|__na|enhancer 
SLC43A1 ENSG00000149150 protein_coding -0.400 2.345 0.016 rna|__na|enhancer 
SLC38A5 ENSG00000017483 protein_coding 1.088 2.946 0.024 rna|__na|enhancer 
SLC35B1 ENSG00000121073 protein_coding 0.360 4.834 0.012 rna|__na|enhancer 
SLC2A5 ENSG00000142583 protein_coding 1.656 3.203 0.009 rna|__na|enhancer 
SLC2A12 ENSG00000146411 protein_coding 0.854 4.881 0.019 rna|__na|enhancer 
SLC24A3 ENSG00000185052 protein_coding 1.125 0.991 0.029 rna|promoter|enhancer 
SLC15A4 ENSG00000139370 protein_coding 0.474 4.498 0.008 rna|__na|enhancer 
SIDT2 ENSG00000149577 protein_coding -0.527 5.426 0.003 rna|__na|enhancer 
SH3RF2 ENSG00000156463 protein_coding -0.872 1.651 0.016 rna|__na|enhancer 
SH3BP5 ENSG00000131370 protein_coding 0.473 5.773 0.011 rna|__na|enhancer 
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SGPL1 ENSG00000166224 protein_coding 0.340 3.414 0.024 rna|__na|enhancer 
SGK1 ENSG00000118515 protein_coding 1.478 6.384 0.002 rna|__na|enhancer 
SETBP1 ENSG00000152217 protein_coding -0.724 5.050 0.005 rna|__na|enhancer 
SERTAD4 ENSG00000082497 protein_coding -0.453 7.270 0.021 rna|__na|enhancer 
SERPINE2 ENSG00000135919 protein_coding 1.462 8.253 0.006 rna|__na|enhancer 
SERPINA3 ENSG00000196136 protein_coding -0.695 11.820 0.007 rna|__na|enhancer 
SEMA6C ENSG00000143434 protein_coding -0.441 2.208 0.031 rna|__na|enhancer 
SEMA5A ENSG00000112902 protein_coding 1.319 2.745 0.023 rna|__na|enhancer 
SEC22A ENSG00000121542 protein_coding 0.292 3.290 0.043 rna|__na|enhancer 
SEC11C ENSG00000166562 protein_coding 0.325 4.297 0.037 rna|__na|enhancer 
SDC3 ENSG00000162512 protein_coding -1.094 7.039 0.002 rna|__na|enhancer 
SCUBE2 ENSG00000175356 protein_coding -0.996 3.976 0.003 rna|__na|enhancer 
SCN4A ENSG00000007314 protein_coding -1.370 -0.192 0.006 rna|__na|enhancer 
S100B ENSG00000160307 protein_coding -0.500 7.558 0.018 rna|__na|enhancer 
RTN4RL1 ENSG00000185924 protein_coding -0.755 4.608 0.003 rna|__na|enhancer 
RTKN2 ENSG00000182010 protein_coding 1.844 -1.662 0.004 rna|promoter|__na 
RRM2 ENSG00000171848 protein_coding 1.323 0.713 0.023 rna|__na|enhancer 
RPS8 ENSG00000142937 protein_coding 0.367 9.224 0.031 rna|__na|enhancer 
RPS3A ENSG00000145425 protein_coding 0.395 10.041 0.034 rna|__na|enhancer 
RPS19 ENSG00000105372 protein_coding 0.361 8.087 0.041 rna|__na|enhancer 
RP11-182J1.16 ENSG00000259511 protein_coding -1.361 2.230 0.007 rna|__na|enhancer 
RP11-111M22.2 ENSG00000179240 protein_coding -0.586 1.627 0.028 rna|__na|enhancer 
RORA ENSG00000069667 protein_coding 0.554 6.170 0.005 rna|__na|enhancer 
ROR2 ENSG00000169071 protein_coding -0.770 4.836 0.005 rna|__na|enhancer 
ROR1 ENSG00000185483 protein_coding 0.809 2.676 0.041 rna|promoter|enhancer 
RNF167 ENSG00000108523 protein_coding -0.269 5.495 0.040 rna|__na|enhancer 
RNF152 ENSG00000176641 protein_coding 0.929 4.860 0.010 rna|__na|enhancer 
RNF150 ENSG00000170153 protein_coding -0.982 1.364 0.046 rna|promoter|__na 
RNF139 ENSG00000170881 protein_coding 0.531 4.985 0.003 rna|__na|enhancer 
RIT1 ENSG00000143622 protein_coding 0.482 3.384 0.009 rna|__na|enhancer 
RHPN2 ENSG00000131941 protein_coding 0.896 0.896 0.041 rna|promoter|__na 
RHOBTB3 ENSG00000164292 protein_coding -0.292 6.193 0.046 rna|__na|enhancer 
RGAG4 ENSG00000242732 protein_coding -0.539 3.249 0.006 rna|__na|enhancer 
REEP3 ENSG00000165476 protein_coding 0.298 6.148 0.024 rna|__na|enhancer 
RDH14 ENSG00000240857 protein_coding 0.442 3.161 0.008 rna|__na|enhancer 
RBBP8 ENSG00000101773 protein_coding 0.526 3.032 0.013 rna|__na|enhancer 
RASL11B ENSG00000128045 protein_coding 1.044 -0.670 0.018 rna|__na|enhancer 
RARRES2 ENSG00000106538 protein_coding -1.381 4.048 0.029 rna|__na|enhancer 
RAD51AP2 ENSG00000214842 protein_coding 1.346 0.218 0.007 rna|promoter|__na 
RAD51AP1 ENSG00000111247 protein_coding 1.037 -0.071 0.013 rna|__na|enhancer 
RAD51 ENSG00000051180 protein_coding 1.499 -0.842 0.017 rna|__na|enhancer 
RAB36 ENSG00000100228 protein_coding -0.479 1.528 0.037 rna|__na|enhancer 
PTPRS ENSG00000105426 protein_coding -0.823 5.880 0.005 rna|__na|enhancer 
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PTGES ENSG00000148344 protein_coding 1.382 5.799 0.022 rna|__na|enhancer 
PSMD6 ENSG00000163636 protein_coding 0.440 4.922 0.008 rna|__na|enhancer 
PSMD1 ENSG00000173692 protein_coding 0.346 6.124 0.012 rna|__na|enhancer 
PRUNE ENSG00000143363 protein_coding -0.225 4.204 0.043 rna|__na|enhancer 
PREX1 ENSG00000124126 protein_coding -0.481 6.731 0.007 rna|__na|enhancer 
PRDM11 ENSG00000019485 protein_coding -0.433 3.395 0.013 rna|__na|enhancer 
PRDM1 ENSG00000057657 protein_coding 1.993 0.552 0.012 rna|promoter|__na 
PPP1R32 ENSG00000162148 protein_coding -0.841 0.333 0.031 rna|__na|enhancer 
PPHLN1 ENSG00000134283 protein_coding 0.208 4.873 0.032 rna|__na|enhancer 
POMGNT2 ENSG00000144647 protein_coding -0.270 3.373 0.031 rna|__na|enhancer 
POM121C ENSG00000135213 protein_coding -0.331 4.500 0.013 rna|__na|enhancer 
PODXL2 ENSG00000114631 protein_coding 0.593 2.728 0.031 rna|promoter|__na 
PODXL ENSG00000128567 protein_coding 0.711 3.452 0.044 rna|promoter|__na 
PMAIP1 ENSG00000141682 protein_coding 1.645 0.408 0.005 rna|promoter|__na 
PLEKHG3 ENSG00000126822 protein_coding -0.312 4.554 0.031 rna|__na|enhancer 
PLEKHA6 ENSG00000143850 protein_coding -0.794 0.559 0.025 rna|__na|enhancer 
PLCG1 ENSG00000124181 protein_coding -0.491 5.668 0.004 rna|__na|enhancer 
PIK3R1 ENSG00000145675 protein_coding -0.728 7.355 0.012 rna|__na|enhancer 
PIGN ENSG00000197563 protein_coding 0.365 4.455 0.047 rna|__na|enhancer 
PHF10 ENSG00000130024 protein_coding 0.250 6.229 0.032 rna|__na|enhancer 
PEG3 ENSG00000198300 protein_coding -0.676 4.470 0.037 rna|__na|enhancer 
PDE4D ENSG00000113448 protein_coding 0.406 5.320 0.035 rna|__na|enhancer 
PAX1 ENSG00000125813 protein_coding 2.901 0.192 0.011 rna|promoter|__na 
PAK1IP1 ENSG00000111845 protein_coding 0.312 3.876 0.022 rna|__na|enhancer 
P4HA3 ENSG00000149380 protein_coding 1.179 5.227 0.026 rna|promoter|__na 
OSBPL3 ENSG00000070882 protein_coding 0.923 3.404 0.023 rna|__na|enhancer 
ODC1 ENSG00000115758 protein_coding 0.430 4.999 0.012 rna|__na|enhancer 
OBSCN ENSG00000154358 protein_coding -1.109 4.559 0.004 rna|__na|enhancer 
NUDCD1 ENSG00000120526 protein_coding 0.307 3.438 0.038 rna|__na|enhancer 
NTRK3 ENSG00000140538 protein_coding -2.662 1.025 0.012 rna|__na|enhancer 
NT5E ENSG00000135318 protein_coding 1.030 8.599 0.007 rna|__na|enhancer 
NRIP3 ENSG00000175352 protein_coding 1.058 0.488 0.040 rna|promoter|__na 
NPR3 ENSG00000113389 protein_coding 2.465 2.818 0.015 rna|__na|enhancer 
NPAS2 ENSG00000170485 protein_coding -0.341 3.710 0.041 rna|__na|enhancer 
NOA1 ENSG00000084092 protein_coding 0.279 3.812 0.031 rna|__na|enhancer 
NKX3-2 ENSG00000109705 protein_coding -0.622 4.697 0.009 rna|__na|enhancer 
NGF ENSG00000134259 protein_coding 1.333 3.034 0.016 rna|__na|enhancer 
NFIL3 ENSG00000165030 protein_coding 1.019 5.284 0.049 rna|__na|enhancer 
NFIA ENSG00000162599 protein_coding -0.461 5.533 0.030 rna|__na|enhancer 
NFATC2 ENSG00000101096 protein_coding 0.581 7.142 0.047 rna|__na|enhancer 
NEDD9 ENSG00000111859 protein_coding 1.074 3.556 0.010 rna|__na|enhancer 
NDUFB9 ENSG00000147684 protein_coding 0.315 5.190 0.015 rna|__na|enhancer 
NCOA6 ENSG00000198646 protein_coding -0.350 4.579 0.044 rna|__na|enhancer 
 49 
NALCN ENSG00000102452 protein_coding 1.559 -1.609 0.032 rna|__na|enhancer 
NAE1 ENSG00000159593 protein_coding 0.294 4.681 0.035 rna|__na|enhancer 
MYO6 ENSG00000196586 protein_coding 0.509 4.479 0.006 rna|__na|enhancer 
MYO5A ENSG00000197535 protein_coding 0.425 4.907 0.012 rna|__na|enhancer 
MYO1B ENSG00000128641 protein_coding 0.771 6.002 0.002 rna|__na|enhancer 
MYH14 ENSG00000105357 protein_coding -1.436 3.634 0.003 rna|__na|enhancer 
MUC20 ENSG00000176945 protein_coding -0.909 3.817 0.004 rna|__na|enhancer 
MTSS1L ENSG00000132613 protein_coding -0.649 5.099 0.004 rna|__na|enhancer 
MTSS1 ENSG00000170873 protein_coding 1.419 2.252 0.037 rna|promoter|enhancer 
MSX2 ENSG00000120149 protein_coding 2.936 2.620 0.003 rna|promoter|enhancer 
MRPS10 ENSG00000048544 protein_coding 0.409 3.721 0.009 rna|__na|enhancer 
MPPED2 ENSG00000066382 protein_coding -1.089 3.342 0.004 rna|__na|enhancer 
MOK ENSG00000080823 protein_coding -0.360 2.886 0.015 rna|__na|enhancer 
MITF ENSG00000187098 protein_coding 0.466 2.798 0.031 rna|__na|enhancer 
MICAL2 ENSG00000133816 protein_coding 0.696 5.435 0.048 rna|__na|enhancer 
MFSD11 ENSG00000092931 protein_coding 0.366 4.359 0.005 rna|__na|enhancer 
MFHAS1 ENSG00000147324 protein_coding -0.506 3.654 0.016 rna|__na|enhancer 
MERTK ENSG00000153208 protein_coding -0.545 1.992 0.008 rna|__na|enhancer 
MED13 ENSG00000108510 protein_coding 0.397 5.277 0.018 rna|__na|enhancer 
MARK2 ENSG00000072518 protein_coding -0.338 3.796 0.029 rna|__na|enhancer 
MAP3K2 ENSG00000169967 protein_coding 0.336 5.784 0.029 rna|__na|enhancer 
MAP1B ENSG00000131711 protein_coding 1.137 3.415 0.020 rna|promoter|__na 
MAOB ENSG00000069535 protein_coding -0.746 7.116 0.004 rna|__na|enhancer 
MAF ENSG00000178573 protein_coding -0.853 5.480 0.005 rna|__na|enhancer 
LZTS1 ENSG00000061337 protein_coding -0.582 3.299 0.010 rna|__na|enhancer 
LRRC8C ENSG00000171488 protein_coding 1.387 3.940 0.004 rna|__na|enhancer 
LRRC8B ENSG00000197147 protein_coding 0.932 0.948 0.018 rna|__na|enhancer 
LRRC1 ENSG00000137269 protein_coding 0.417 3.645 0.038 rna|__na|enhancer 
LRP5L ENSG00000100068 protein_coding -0.736 0.903 0.011 rna|__na|enhancer 
LRP5 ENSG00000162337 protein_coding -0.637 4.529 0.004 rna|__na|enhancer 
LRP11 ENSG00000120256 protein_coding 0.227 5.707 0.037 rna|__na|enhancer 
LRIG1 ENSG00000144749 protein_coding -0.707 6.054 0.005 rna|__na|enhancer 
LIMCH1 ENSG00000064042 protein_coding -0.420 7.594 0.012 rna|__na|enhancer 
LGALS3 ENSG00000131981 protein_coding 0.494 8.066 0.005 rna|__na|enhancer 
LEMD2 ENSG00000161904 protein_coding -0.194 4.783 0.039 rna|__na|enhancer 
LAMA1 ENSG00000101680 protein_coding -0.673 -0.077 0.035 rna|__na|enhancer 
KRBOX1 ENSG00000273291 protein_coding -1.406 0.616 0.014 rna|__na|enhancer 
KIAA1161 ENSG00000164976 protein_coding -0.716 3.857 0.010 rna|__na|enhancer 
KIAA0196 ENSG00000164961 protein_coding 0.220 4.952 0.043 rna|__na|enhancer 
KCNS3 ENSG00000170745 protein_coding 1.539 1.810 0.009 rna|promoter|enhancer 
KCNIP3 ENSG00000115041 protein_coding -0.743 1.775 0.025 rna|__na|enhancer 
KCNH1 ENSG00000143473 protein_coding -1.441 -1.122 0.021 rna|__na|enhancer 
ITPR1 ENSG00000150995 protein_coding 0.610 4.126 0.022 rna|__na|enhancer 
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ITIH5 ENSG00000123243 protein_coding -0.432 6.401 0.038 rna|__na|enhancer 
ITGA4 ENSG00000115232 protein_coding 1.315 0.163 0.005 rna|promoter|__na 
INHBA ENSG00000122641 protein_coding 0.853 7.680 0.013 rna|__na|enhancer 
IL17RB ENSG00000056736 protein_coding -1.051 4.866 0.010 rna|__na|enhancer 
IL11 ENSG00000095752 protein_coding 4.101 3.706 0.025 rna|promoter|__na 
IGFBP7 ENSG00000163453 protein_coding 1.279 8.044 0.012 rna|promoter|enhancer 
IFT122 ENSG00000163913 protein_coding -0.336 4.155 0.025 rna|__na|enhancer 
IAH1 ENSG00000134330 protein_coding 0.376 4.600 0.008 rna|__na|enhancer 
HUNK ENSG00000142149 protein_coding 1.600 1.033 0.006 rna|promoter|__na 
HSD3B7 ENSG00000099377 protein_coding 0.755 4.794 0.022 rna|__na|enhancer 
HOXD8 ENSG00000175879 protein_coding 0.368 4.581 0.024 rna|__na|enhancer 
HOXB2 ENSG00000173917 protein_coding 1.598 2.415 0.003 rna|promoter|__na 
HMGA2 ENSG00000149948 protein_coding 2.064 0.218 0.021 rna|promoter|__na 
HES6 ENSG00000144485 protein_coding 2.010 -0.460 0.008 rna|promoter|__na 
HDDC2 ENSG00000111906 protein_coding 0.240 5.493 0.043 rna|__na|enhancer 
HAT1 ENSG00000128708 protein_coding 0.321 5.105 0.014 rna|__na|enhancer 
HAAO ENSG00000162882 protein_coding -0.518 2.814 0.016 rna|__na|enhancer 
H6PD ENSG00000049239 protein_coding -0.308 6.176 0.027 rna|__na|enhancer 
GUCY1A3 ENSG00000164116 protein_coding -0.987 3.738 0.021 rna|__na|enhancer 
GSTO2 ENSG00000065621 protein_coding -0.498 3.029 0.011 rna|__na|enhancer 
GRIN2C ENSG00000161509 protein_coding -1.120 2.442 0.012 rna|__na|enhancer 
GRIA2 ENSG00000120251 protein_coding 1.587 3.646 0.011 rna|promoter|__na 
GRAMD1A ENSG00000089351 protein_coding -0.392 4.548 0.023 rna|__na|enhancer 
GPR176 ENSG00000166073 protein_coding 0.765 2.567 0.017 rna|promoter|__na 
GPC4 ENSG00000076716 protein_coding 1.304 2.329 0.005 rna|promoter|__na 
GMDS ENSG00000112699 protein_coding -0.517 5.421 0.003 rna|__na|enhancer 
GLYATL2 ENSG00000156689 protein_coding 1.620 0.501 0.011 rna|promoter|__na 
GGT7 ENSG00000131067 protein_coding -0.349 4.511 0.014 rna|__na|enhancer 
GDF7 ENSG00000143869 protein_coding -1.549 1.799 0.012 rna|promoter|__na 
GDF10 ENSG00000107623 protein_coding -1.052 9.343 0.007 rna|__na|enhancer 
GALNT13 ENSG00000144278 protein_coding 1.361 1.879 0.041 rna|promoter|__na 
FZD10 ENSG00000111432 protein_coding 1.037 2.677 0.029 rna|__na|enhancer 
FXYD3 ENSG00000089356 protein_coding -0.877 1.288 0.018 rna|__na|enhancer 
FSTL3 ENSG00000070404 protein_coding 0.936 4.046 0.029 rna|promoter|enhancer 
FOXF1 ENSG00000103241 protein_coding 2.301 0.558 0.003 rna|__na|enhancer 
FNIP2 ENSG00000052795 protein_coding 0.880 5.953 0.007 rna|__na|enhancer 
FHL2 ENSG00000115641 protein_coding 1.012 3.541 0.007 rna|promoter|__na 
FGFR2 ENSG00000066468 protein_coding -0.780 7.732 0.008 rna|__na|enhancer 
FGF9 ENSG00000102678 protein_coding 1.811 0.395 0.012 rna|promoter|__na 
FGD6 ENSG00000180263 protein_coding -0.696 2.469 0.028 rna|__na|enhancer 
FDX1 ENSG00000137714 protein_coding 0.645 2.569 0.025 rna|__na|enhancer 
FBRSL1 ENSG00000112787 protein_coding -0.392 3.527 0.032 rna|__na|enhancer 
FBLN7 ENSG00000144152 protein_coding -1.049 7.333 0.003 rna|__na|enhancer 
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FBLN2 ENSG00000163520 protein_coding 1.001 2.610 0.038 rna|__na|enhancer 
FAM78B ENSG00000188859 protein_coding -1.262 1.303 0.010 rna|__na|enhancer 
FAM63A ENSG00000143409 protein_coding -0.436 3.875 0.005 rna|__na|enhancer 
FAM198A ENSG00000144649 protein_coding -1.292 3.383 0.006 rna|__na|enhancer 
FAM177B ENSG00000197520 protein_coding 1.283 -1.178 0.024 rna|__na|enhancer 
FAM101A ENSG00000178882 protein_coding -1.343 3.618 0.005 rna|__na|enhancer 
F3 ENSG00000117525 protein_coding 1.053 1.364 0.011 rna|__na|enhancer 
ETV4 ENSG00000175832 protein_coding 0.661 1.514 0.045 rna|__na|enhancer 
ETS1 ENSG00000134954 protein_coding -0.541 6.914 0.008 rna|__na|enhancer 
ERG ENSG00000157554 protein_coding -0.446 7.201 0.027 rna|__na|enhancer 
EPB41L1 ENSG00000088367 protein_coding -0.371 5.463 0.005 rna|__na|enhancer 
EMP2 ENSG00000213853 protein_coding -0.289 7.159 0.043 rna|__na|enhancer 
EML1 ENSG00000066629 protein_coding 0.429 5.921 0.022 rna|__na|enhancer 
ELK4 ENSG00000158711 protein_coding 0.480 4.755 0.010 rna|promoter|__na 
EHD3 ENSG00000013016 protein_coding -0.479 5.434 0.020 rna|__na|enhancer 
EGR2 ENSG00000122877 protein_coding 1.401 3.775 0.030 rna|__na|enhancer 
EEPD1 ENSG00000122547 protein_coding -0.795 1.067 0.027 rna|__na|enhancer 
ECH1 ENSG00000104823 protein_coding -0.310 4.932 0.017 rna|__na|enhancer 
EBF3 ENSG00000108001 protein_coding 2.084 0.823 0.007 rna|promoter|__na 
DYSF ENSG00000135636 protein_coding 0.853 5.391 0.022 rna|__na|enhancer 
DYNC1I1 ENSG00000158560 protein_coding -0.781 5.033 0.003 rna|__na|enhancer 
DUSP4 ENSG00000120875 protein_coding 1.594 1.733 0.014 rna|promoter|enhancer 
DSG2 ENSG00000046604 protein_coding 1.047 5.995 0.006 rna|__na|enhancer 
DNAJC22 ENSG00000178401 protein_coding 1.021 2.997 0.004 rna|promoter|__na 
DLX4 ENSG00000108813 protein_coding 0.759 3.289 0.039 rna|promoter|__na 
DLGAP1 ENSG00000170579 protein_coding -0.993 0.174 0.032 rna|__na|enhancer 
DKK3 ENSG00000050165 protein_coding 1.224 8.156 0.010 rna|promoter|__na 
DIRAS1 ENSG00000176490 protein_coding 1.113 3.654 0.004 rna|promoter|enhancer 
DHX32 ENSG00000089876 protein_coding 0.222 3.886 0.040 rna|__na|enhancer 
DENND2D ENSG00000162777 protein_coding -0.474 3.539 0.019 rna|__na|enhancer 
DEGS1 ENSG00000143753 protein_coding 0.329 6.165 0.027 rna|__na|enhancer 
DCUN1D3 ENSG00000188215 protein_coding 0.346 2.764 0.047 rna|__na|enhancer 
DCC ENSG00000187323 protein_coding -2.581 3.705 0.002 rna|promoter|__na 
DAAM2 ENSG00000146122 protein_coding -0.491 6.506 0.006 rna|__na|enhancer 
CYP27B1 ENSG00000111012 protein_coding 0.614 1.216 0.032 rna|promoter|__na 
CUL4A ENSG00000139842 protein_coding 0.229 5.059 0.041 rna|__na|enhancer 
CTNNB1 ENSG00000168036 protein_coding 0.358 7.674 0.016 rna|__na|enhancer 
CTGF ENSG00000118523 protein_coding 0.585 12.225 0.019 rna|__na|enhancer 
CSDC2 ENSG00000172346 protein_coding 1.010 1.204 0.032 rna|__na|enhancer 
CSAD ENSG00000139631 protein_coding -0.436 3.639 0.042 rna|__na|enhancer 
CRYL1 ENSG00000165475 protein_coding -0.313 4.471 0.044 rna|__na|enhancer 
CRTC3 ENSG00000140577 protein_coding -0.203 4.521 0.049 rna|__na|enhancer 
CRLF1 ENSG00000006016 protein_coding 2.165 7.398 0.010 rna|promoter|__na 
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CREB1 ENSG00000118260 protein_coding 0.228 4.633 0.041 rna|__na|enhancer 
COMMD2 ENSG00000114744 protein_coding 0.343 4.606 0.029 rna|__na|enhancer 
COLCA2 ENSG00000214290 protein_coding -1.087 -0.929 0.017 rna|__na|enhancer 
COL9A3 ENSG00000092758 protein_coding -0.820 10.899 0.009 rna|__na|enhancer 
COL8A1 ENSG00000144810 protein_coding 2.144 4.563 0.015 rna|__na|enhancer 
COL18A1 ENSG00000182871 protein_coding 1.128 5.301 0.008 rna|promoter|__na 
CNOT7 ENSG00000198791 protein_coding 0.223 5.540 0.025 rna|__na|enhancer 
CMTM4 ENSG00000183723 protein_coding 0.333 4.265 0.027 rna|__na|enhancer 
CLDN23 ENSG00000253958 protein_coding -0.753 1.770 0.029 rna|__na|enhancer 
CITED4 ENSG00000179862 protein_coding 1.306 1.866 0.015 rna|__na|enhancer 
CHRDL2 ENSG00000054938 protein_coding -1.515 8.084 0.005 rna|__na|enhancer 
CHRD ENSG00000090539 protein_coding 0.603 3.273 0.023 rna|promoter|__na 
CHDH ENSG00000016391 protein_coding -0.682 4.440 0.014 rna|__na|enhancer 
CFDP1 ENSG00000153774 protein_coding -0.355 5.283 0.030 rna|__na|enhancer 
CENPK ENSG00000123219 protein_coding 1.003 1.011 0.017 rna|__na|enhancer 
CDYL2 ENSG00000166446 protein_coding 0.994 1.505 0.029 rna|promoter|__na 
CDC42EP3 ENSG00000163171 protein_coding -0.925 5.279 0.008 rna|__na|enhancer 
CCRN4L ENSG00000151014 protein_coding 0.887 0.826 0.021 rna|__na|enhancer 
CCNYL1 ENSG00000163249 protein_coding 0.598 3.472 0.007 rna|__na|enhancer 
CCNDBP1 ENSG00000166946 protein_coding 0.227 4.633 0.026 rna|__na|enhancer 
CCND1 ENSG00000110092 protein_coding 0.897 5.222 0.014 rna|promoter|__na 
CCDC91 ENSG00000123106 protein_coding 0.428 3.801 0.012 rna|__na|enhancer 
CCDC85A ENSG00000055813 protein_coding -0.555 5.237 0.009 rna|__na|enhancer 
CCDC25 ENSG00000147419 protein_coding 0.320 5.247 0.010 rna|__na|enhancer 
CAMTA2 ENSG00000108509 protein_coding -0.396 4.188 0.022 rna|__na|enhancer 
CALU ENSG00000128595 protein_coding 0.357 8.873 0.019 rna|__na|enhancer 
CAAP1 ENSG00000120159 protein_coding 0.506 3.046 0.009 rna|__na|enhancer 
C7orf73 ENSG00000243317 protein_coding 0.341 6.199 0.048 rna|__na|enhancer 
C6orf132 ENSG00000188112 protein_coding 1.123 0.820 0.021 rna|promoter|enhancer 
C4orf46 ENSG00000205208 protein_coding 0.658 1.770 0.015 rna|__na|enhancer 
C4BPA ENSG00000123838 protein_coding -0.960 3.526 0.005 rna|__na|enhancer 
C2orf69 ENSG00000178074 protein_coding 0.621 3.563 0.003 rna|__na|enhancer 
C1orf56 ENSG00000143443 protein_coding -0.553 1.083 0.043 rna|__na|enhancer 
C17orf72 ENSG00000224383 protein_coding -1.244 0.803 0.005 rna|__na|enhancer 
C16orf72 ENSG00000182831 protein_coding 0.307 5.365 0.017 rna|__na|enhancer 
C12orf60 ENSG00000182993 protein_coding 0.385 1.474 0.049 rna|__na|enhancer 
BRD4 ENSG00000141867 protein_coding -0.360 4.734 0.036 rna|__na|enhancer 
BOC ENSG00000144857 protein_coding -0.820 7.744 0.003 rna|__na|enhancer 
BMPR1B ENSG00000138696 protein_coding 2.309 0.063 0.009 rna|promoter|enhancer 
BEGAIN ENSG00000183092 protein_coding -0.472 2.133 0.011 rna|__na|enhancer 
BDNF ENSG00000176697 protein_coding 1.622 -0.641 0.011 rna|__na|enhancer 
BCAR3 ENSG00000137936 protein_coding -0.300 3.508 0.016 rna|__na|enhancer 
BAALC ENSG00000164929 protein_coding 0.958 5.777 0.004 rna|__na|enhancer 
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ATP5H ENSG00000167863 protein_coding 0.415 5.820 0.005 rna|__na|enhancer 
ATP5A1 ENSG00000152234 protein_coding 0.376 7.280 0.036 rna|__na|enhancer 
ATP13A2 ENSG00000159363 protein_coding -0.395 2.971 0.022 rna|__na|enhancer 
ASAP2 ENSG00000151693 protein_coding 0.594 6.664 0.008 rna|__na|enhancer 
ARSI ENSG00000183876 protein_coding 0.812 2.258 0.018 rna|__na|enhancer 
ARPP19 ENSG00000128989 protein_coding 0.245 6.229 0.037 rna|__na|enhancer 
ARMC10 ENSG00000170632 protein_coding 0.311 4.615 0.018 rna|__na|enhancer 
ARHGEF4 ENSG00000136002 protein_coding -0.518 2.289 0.043 rna|__na|enhancer 
ARHGAP44 ENSG00000006740 protein_coding 1.159 1.745 0.009 rna|__na|enhancer 
ARHGAP29 ENSG00000137962 protein_coding -0.327 5.135 0.050 rna|__na|enhancer 
ARFGAP3 ENSG00000242247 protein_coding 0.379 6.190 0.048 rna|__na|enhancer 
AP2S1 ENSG00000042753 protein_coding 0.448 4.097 0.045 rna|__na|enhancer 
ANXA4 ENSG00000196975 protein_coding 0.416 6.738 0.011 rna|__na|enhancer 
AMPD3 ENSG00000133805 protein_coding -0.299 3.017 0.033 rna|__na|enhancer 
ALS2CR11 ENSG00000155754 protein_coding 0.601 0.577 0.021 rna|__na|enhancer 
ALS2CL ENSG00000178038 protein_coding 0.893 3.598 0.013 rna|__na|enhancer 
AKAP8L ENSG00000011243 protein_coding -0.233 4.589 0.035 rna|__na|enhancer 
AKAP11 ENSG00000023516 protein_coding 0.313 5.444 0.027 rna|__na|enhancer 
AIDA ENSG00000186063 protein_coding 0.342 5.349 0.014 rna|__na|enhancer 
AGPS ENSG00000018510 protein_coding 0.602 4.567 0.003 rna|__na|enhancer 
ADTRP ENSG00000111863 protein_coding 1.106 3.629 0.008 rna|__na|enhancer 
ADPRHL1 ENSG00000153531 protein_coding 0.830 3.146 0.024 rna|__na|enhancer 
ADO ENSG00000181915 protein_coding 0.298 3.953 0.024 rna|__na|enhancer 
ADCY3 ENSG00000138031 protein_coding -0.397 5.069 0.017 rna|__na|enhancer 
ADAMTS6 ENSG00000049192 protein_coding 1.207 5.473 0.006 rna|__na|enhancer 
ADAMTS14 ENSG00000138316 protein_coding 1.713 1.638 0.034 rna|__na|enhancer 
ACCS ENSG00000110455 protein_coding -0.431 2.829 0.038 rna|__na|enhancer 
AC104532.2 ENSG00000267314 protein_coding 0.723 2.902 0.025 rna|__na|enhancer 
ABHD2 ENSG00000140526 protein_coding 0.533 7.313 0.018 rna|__na|enhancer 
AAAS ENSG00000094914 protein_coding -0.357 4.555 0.016 rna|__na|enhancer 
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Figure 3-1 The ATAC-seq pipeline schematic.  
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Figure 3-2 Normalized nucleoATAC signal aggregated over all genes shows distinct 
nucleosome positioning around transcription start sites (TSS).  
Positive and negative numbers (+1, +2, +3, -1, -2) indicate the TSS upstream and 
downstream nucleosomes. 
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Figure 3-3 Annotation of identified accessible chromatin regions.  
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Figure 3-4 Identification of accessible chromatin regions with OA susceptible GWAS 
SNPs and DMLs. 
An example of an OA GWAS SNP rs11731421 (up) and differentially methylated locus 
cg09221159 (down) overlapping with an open enhancer in cartilages from OA patients. 
The arrow points to the predicted target genes. 
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Figure 3-5 Principal component analysis on the peak signals across the 16 samples. 
PC1: separation between oLT and iMT; PC2: separation between each patient. 
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Figure 3-6 Peaks with smaller FDR (i.e. more confident to be differentially 
accessible) contain more enhancer peaks. 
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Figure 3-7 Significantly differentially accessible peaks with FDR  0.05.  
Pie chart shows proportions of the ATAC-seq peaks that are more accessible in iMT 
(red) and oLT (blue). 
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Figure 3-8 Genome browser views of dysregulated promoters and enhancers.  
Example loci (all patients pooled) showing differential accessible regions at promoters 
(top) and enhancers (bottom) with more accessible in iMT (left), more accessible in 
oLT (middle), and not significantly altered between oLT and iMT (right). 
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Figure 3-9 Genome browser views of consistency.  
Genome browser views showing consistency of ATAC-seq signals across patients at 
examples loci. 
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Figure 3-10 Enrichment of cell type-specific enhancers in differentially accessible 
peaks. 
Top 10 are listed (inset), which includes bone- and chondrocyte-related cell types (bold). 
Error bars represent 95% confidence interval.  
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Figure 3-11 DNA motif analysis.  
Top de novo motif (top) and top predicted known transcription factors (bottom) 
enriched in differentially accessible regions. 
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Figure 3-12 A scheme of ATAC-seq and RNA-seq integration analysis. 
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Figure 3-13 Integration of RNA-seq and ATAC-seq. 
Differential chromatin accessibility (ATAC-seq) at both promoter (left) and enhancer 
(right) in OA is generally consistent with differential expression (RNA-seq). Fold 
change between iMT and oLT is plotted. Box plots show the median, quartiles, and 
Tukey whiskers. 
  
 67 
 
 
 
 
 
 
Figure 3-14 Venn diagram. 
Venn diagram summarizing protein-coding genes that are dysregulated at both the 
transcriptomic (RNA-seq) and epigenomic (ATAC-seq) levels in OA with concordant 
direction of change. 
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Figure 3-15 GO enrichment. 
GO enrichment analysis of 371 dysregulated protein coding genes observed by both 
ATAC-seq and RNA-seq analysis. Top 30 terms in GO biological process ranked by 
the level of enrichment and overlapping dysregulated genes are listed. Terms related to 
MSC, bones, and chondrocytes are highlight in bold.  
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Chapter 4 Conclusions and future research 
 
4.1 Conclusions 
OA is a degenerative joint disease with increasing impact in an aging society 
and that is the most common causes of Chronic disability in the world. The knee OA is 
the most common. Normally used method for OA diagnosis is X-ray imaging. 
Hallmarks of OA include joint space narrowing, cartilage degradation, osteophytes 
formation and subchondral bone thickening. Risk factors such as aging, obesity, gender 
and genetic factors have been identified previously, however, the pathogenesis remains 
incompletely understood. The joint tissue from replacement surgery has been used as a 
model for studying OA disease progression by comparing the cartilage from preserved 
joint space region (oLT; containing intact cartilage) and less join space region (iMT; 
containing damaged cartilage). The transcriptome assay of this model has been 
characterized previously.  It has been identified that the chondrocytes from the intact 
cartilage region of OA patient have similar gene expression level with non-OA cartilage, 
indicating that the intact region cartilage is able to be served as a positive control. 
Transcriptomic analyses of cartilage provided an opportunity to pinpoint 
transcriptionally dysregulated genes and pathways relevant to OA. However, such 
studies have yet to fully reveal the underlying molecular mechanism of how the 
transcription of these genes are dysregulated. The epigenetic regulations can gain more 
insight to the disease pathogenesis. Epigenetic modification can regulate gene 
expression without changing the DNA sequence including DNA methylation, 
chromatin accessibility, DNA binding proteins, histone modifications and non-coding 
RNAs. It is known that gene regulatory regions such as promoter and enhancers that 
play roles in regulation of gene expression. The active promoters and enhancers are 
chromatin accessible regions which allow the binding proteins (i.e. transcription factors) 
to access into. ATAC-seq is a method to profile the chromatin accessible regions 
globally by using Nextera Tn5 transposase. This study was designed to investigate 
alterations of enhancers or promoters associated with OA by applying ATAC-seq on 
the knee joint cartilages from OA patients. Fresh human cartilage has been identified 
to be more suitable than the flash frozen human cartilage to generate high-quality 
ATAC-seq data using collagenase II.  
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Multi-omics profiling of tissues can provide insight into the molecular 
pathogenesis of a disease. While earlier works have been focused on detecting causal 
genetic variant for disorders, recent technical advances have brought the application of 
transcriptome and DNA methylome analysis to disease-relevant clinical samples. 
However, epigenomic analysis at the chromatin level for diseased tissue can pose a 
larger obstacle due to the requirement of millions of cells. In this study, I took advantage 
of ATAC-seq that it requires much less material than, for example, DNase-seq or 
FAIRE-seq, successfully applied on OA articular knee cartilage, and identified 
genome-wide open chromatin variations potentially associated with OA pathogenesis.   
This study was presented as an application of ATAC-seq in OA in a clinically 
relevant setting. The chromatin accessibility map in cartilage will be a resource for 
future GWAS and DNA methylation studies in OA and other musculoskeletal diseases. 
This study identified altered promoters and enhancers of genes that might be involved 
in the pathogenesis of OA. The analyses suggest aberrant enhancer usage associated 
with MSC differentiation and chondrogenesis in OA. Understanding these molecular 
bases of OA is necessary for future therapeutic intervention.  
At the individual gene level, this result observed chromatin differences 
corresponding to expression changes in diseased tissue for known OA related genes. 
Both of HOXB2 and SOX11 are genes functioning in embryonic-fetal development 
(Casaca et al., 2016; Wang & Neiva, 2008). It has been reported that SOX11 can induce 
cartilage growth plate formation in mouse embryos through promoting Wnt signaling 
(Kato et al., 2015) and contribute joint maintenance through regulating GDF5 (Growth/ 
differentiation factor 5) (Kan et al., 2013). HSD11B1 codes a microsomal enzyme that 
can lead and catalyze the conversion of stress hormone (active glucocorticoid) cortisol 
to an inactive metabolite cortisone, in other words, HSD11B1 reduces cortisone to the 
active hormone cortisol that activates glucocorticoid receptors. Too much stress 
hormone cortisol can induce central obesity and metabolic syndrome (Abraham et al., 
2013). The higher cortisol level is also correlated with higher chronic osteoarthritis pain 
subscale score (Carlesso et al., 2016; Khoromi et al., 2006).   
Moreover, the traditional researches for diseases focus on causal coding genes, 
noncoding genes and regulatory elements which are proved to have critical implication 
in recent years (Esteller, 2011). Among them, long non-coding RNAs (lncRNAs) are 
more likely to be cell-type-specific and proposed to play a regulatory role for gene 
expression. In many cases lncRNAs have been shown to recruit regulatory complexes 
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through RNA-protein interaction or nucleosome remodeling (Geisler & Coller, 2013). 
However, they are usually low abundant and difficult to detect at the RNA level. Here, 
this study utilized ATAC-seq to probe genome-wide chromatin accessibility variation 
including those non-coding RNAs.  
The novel findings in this work have potential to serve as diagnostic or 
therapeutic targets. A validation crossed three different platforms, patients and races 
(European and Japanese) suggest the genes that involved in the endochondral 
ossification signals pathway should be critical for OA development and progression. 
Furthermore, the related regulators can be the clinical therapeutic targets of OA 
progression.  
In addition, mesenchymal stem cell transplantation therapy for curing OA is 
promising but falls stagnant since the way of mesenchymal stem cell mediating healing 
is unclear and could induce abnormal repair (Gupta et al., 2012; Manieri et al., 2015). 
Models for OA initiation (Figure 4-1) proposed to explain pathogenesis such as 
mechanical injury, inflammatory mediators from synovium, defects in metabolism and 
endochondral ossification  (Cox et al., 2013; Dreier, 2010; Kapoor, 2015; Kawaguchi, 
2008, 2016; Kuyinu et al., 2016; Man & Mologhianu, 2014). The results from this work 
are supporting the endochondral theory. In the fetus or child, the bone is formed through 
cartilage turnover processes (i.e. endochondral ossification) including mesenchymal 
stem cell to chondrocyte differentiation, hypertrophic chondrocyte differentiation, and 
osteoblast differentiation. In the adult, cartilage is not capable of regenerating or healing, 
since the mesenchymal stem cell to chondrocyte differentiation is more likely to be 
blocked. However, in OA, with the loss of cartilage and disorder in the joint, the 
mesenchymal stem cell can be forced to differentiate to chondrocyte or osteoblast as a 
self-healing mechanism, similar to endochondral ossification processes that result of 
cartilage turnover to the bone. How to force the chondrocyte to regenerate cartilage will 
be a critical and essential cure for OA patients (Figure 4-2). 
Altogether, I believe the findings are of very high interest to the field, as this 
extensive analysis on ATAC-seq datasets on clinical samples of OA patients could 
expound the possible pathogenesis mechanism, leading to the identification of potential 
targets of biomarkers or therapies. 
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4.2 Future research 
The osteoblast-like signal or ossification signal is from a chondrocyte 
undergoing terminal differentiation, or from MSC direct differentiation cannot be 
distinguished from bulk tissue analysis, but may be revealed by further experiments 
such as single-cell transcriptomics or single-cell ATAC-seq (Haque et al., 2017).  
Single cell RNA-seq and ATAC-seq analysis enable look for candidates signals that are 
responsible for initiating EO differentiation, ligand/receptor that are specific to the 
‘damaged’ tissues. If stopping these signals at the early onset of OA, it may minimize 
the pain the patient may otherwise experience by stop the abnormal healing. Animal 
models can be used for candidate gene functional validation.  
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Figure 4-1 Models for OA initiation proposed to explain pathogenesis of OA. 
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Figure 4-2 Abnormal self-healing theory in OA pathology. 
Mesenchymal stem cells are launched in the OA degenerative joint, as a capacitive for 
self-healing, the positive regulation of osteoblast differentiation in disease inducing the 
bone formation, which is similar as endochondral ossification, the main skeletal 
formation process during fetal growing. 
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